var title_f2_21_2384="HAPE xray";
var content_f2_21_2384=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plain chest x-ray of HAPE",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain chest radiography is useful in HAPE and reveals characteristic patchy alveolar infiltrates, predominantly in the right central hemithorax, which become more confluent and bilateral as the illness progresses. In a few cases, HAPE may not take this classic radiographic appearance",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott A Gallagher, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_21_2384=[""].join("\n");
var outline_f2_21_2384=null;
var title_f2_21_2385="Air bronchogram CT I";
var content_f2_21_2385=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pneumonia with air bronchogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Severe pneumonia with dense consolidation of the right upper lobe and marked air bronchogram formation, characteristic of air space disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_21_2385=[""].join("\n");
var outline_f2_21_2385=null;
var title_f2_21_2386="Patient information: Uterine artery embolization (The Basics)";
var content_f2_21_2386=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86791\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/15/4340\">",
"         Uterine artery embolization",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?6/42/6818\">",
"         Patient information: Anesthesia (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/52/21314\">",
"         Patient information: Uterine fibroids (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/18/22820\">",
"         Patient information: Abnormal uterine bleeding (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/20/20804\">",
"         Patient information: Uterine fibroids (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Uterine artery embolization (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H89192433\">",
"      <span class=\"h1\">",
"       What is uterine artery embolization?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Uterine artery embolization (also called &ldquo;UAE&rdquo;) is a treatment for fibroids. Fibroids are abnormal growths of tissue that form in the uterus, the part of the woman&rsquo;s body that holds the baby if she is pregnant.",
"     </p>",
"     <p>",
"      UAE is also called &ldquo;uterine fibroid embolization.&rdquo; It works by blocking the blood vessels that supply blood to fibroids, causing them to shrink. It is 1 of several ways doctors treat fibroids.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H89192448\">",
"      <span class=\"h1\">",
"       Why might a woman get UAE?",
"      </span>",
"      &nbsp;&mdash;&nbsp;UAE helps ease the heavy bleeding and lower belly pressure caused by fibroids. Compared with surgery to treat fibroids, UAE:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Takes less time",
"       </li>",
"       <li>",
"        Does not require any cuts (incisions) in the belly",
"       </li>",
"       <li>",
"        Has a shorter recovery time",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H89192463\">",
"      <span class=\"h1\">",
"       What are the downsides of UAE?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Compared with women treated with surgery, women treated with UAE are more likely to need a second surgery to control heavy bleeding.",
"     </p>",
"     <p>",
"      UAE does not work well on certain types of fibroids. Also, women who want to get pregnant in the future should not have UAE. Your doctor can help you decide if UAE is right for you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H89192478\">",
"      <span class=\"h1\">",
"       What happens during UAE?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are having UAE, you will be treated in a hospital. You will get medicines (called &ldquo;anesthesia&rdquo;) to block pain in the lower half of your body and to make you feel relaxed. But you will stay awake.",
"     </p>",
"     <p>",
"      The doctor will then insert a thin tube (called a &ldquo;catheter&rdquo;) into the artery at the top of 1 leg and advance it up to your uterus. With the tube in place, the doctor will inject a special dye that can be seen on X-rays to show the arteries that bring blood to the fibroid. Next, the doctor will inject tiny plastic beads into the artery to block the blood flow to the fibroid (",
"      <a class=\"graphic graphic_figure graphicRef86790 \" href=\"UTD.htm?4/15/4340\">",
"       figure 1",
"      </a>",
"      ). Afterward, the doctor will repeat the same steps on the other side. The procedure takes about 1 hour. You will likely stay in the hospital overnight, where nurses can check you and give you pain medicines.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H89192512\">",
"      <span class=\"h1\">",
"       What happens after UAE?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most women have lower belly pain and cramping after the procedure. These symptoms are usually worst the first 2 days after the procedure and can last up to 7 days. Some women have discharge or bleeding from the vagina for 2 weeks after UAE. Sometimes, the bleeding lasts for months.",
"     </p>",
"     <p>",
"      Some women also:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feel sick to their stomach (nausea)",
"       </li>",
"       <li>",
"        Throw up (vomit)",
"       </li>",
"       <li>",
"        Have a fever",
"       </li>",
"       <li>",
"        Feel tired and achy",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have these symptoms, your doctor can prescribe pain relievers and other medicines to treat them.",
"     </p>",
"     <p>",
"      You should see your doctor for several follow-up visits during the first year to check that the procedure worked.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H89192529\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is possible to get pregnant after UAE. But after UAE, pregnancy might not be safe for either the mother or the baby. Because of this, doctors advise women who want to get pregnant NOT to have this procedure. They also advise women to use birth control after the procedure to avoid pregnancy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H89192544\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/52/21314?source=see_link\">",
"       Patient information: Uterine fibroids (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/42/6818?source=see_link\">",
"       Patient information: Anesthesia (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/20/20804?source=see_link\">",
"       Patient information: Uterine fibroids (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/18/22820?source=see_link\">",
"       Patient information: Abnormal uterine bleeding (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?2/21/2386?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86791 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-58B3102C39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_21_2386=[""].join("\n");
var outline_f2_21_2386=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89192433\">",
"      What is uterine artery embolization?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89192448\">",
"      Why might a woman get UAE?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89192463\">",
"      What are the downsides of UAE?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89192478\">",
"      What happens during UAE?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89192512\">",
"      What happens after UAE?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89192529\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89192544\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86791\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/15/4340\">",
"      Uterine artery embolization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/18/22820?source=related_link\">",
"      Patient information: Abnormal uterine bleeding (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/42/6818?source=related_link\">",
"      Patient information: Anesthesia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/20/20804?source=related_link\">",
"      Patient information: Uterine fibroids (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/52/21314?source=related_link\">",
"      Patient information: Uterine fibroids (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_21_2387="MSU crystals in acute gout";
var content_f2_21_2387=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F85631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F85631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    Monosodium urate crystals",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Synovial fluid from a patient with acute gouty arthritis, when viewed with compensated polarized microscopy, reveals needle shaped, birefringent crystals. These monosodium urate crystals are bright yellow when aligned with the axis of the compensator.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of H Ralph Schumacher, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_21_2387=[""].join("\n");
var outline_f2_21_2387=null;
var title_f2_21_2388="Fulvestrant: Pediatric drug information";
var content_f2_21_2388=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fulvestrant: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4964?source=see_link\">",
"    see \"Fulvestrant: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/8/11396?source=see_link\">",
"    see \"Fulvestrant: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F174701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Faslodex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12817149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Faslodex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1015558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Estrogen Receptor Antagonist",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1015592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4964?source=see_link\">",
"      see \"Fulvestrant: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children 1-10 years:",
"     <b>",
"      McCune-Albright Syndrome; progressive precocious puberty:",
"     </b>",
"     Limited data available: I.M.: 4 mg/kg once monthly; dosing based on a trial in 30 girls &le;10 years of age (range: 1-8.5 years) who received monthly injections for 1 year; significant decrease in vaginal bleeding and reduction in rates of skeletal maturation were reported; further studies are needed (Sims, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      Breast cancer, metastatic (postmenopausal women):",
"     </b>",
"     I.M.: Initial: 500 mg on days 1, 15, and 29; Maintenance: 500 mg once monthly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: No dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); however, renal elimination of fulvestrant is negligible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild impairment (Child-Pugh class A): No dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate impairment (Child-Pugh class B): Decrease initial and maintenance doses to 250 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe impairment (Child-Pugh class C): Use has not been evaluated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F174679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Faslodex&reg;: 50 mg/mL (5 mL) [contains benzyl alcohol, benzyl benzoate, castor oil, ethanol 10% w/v]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F174667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1015596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"     <b>",
"      For I.M. administration only; do not administer I.V., SubQ, or intra-arterially.",
"     </b>",
"     In adults, administer 500 mg dose as two 5 mL injections (one in each buttock) slowly over 1-2 minutes per injection; depending upon final dose volume, pediatric patients may be able to receive entire dose as one injection.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1015579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store in original carton at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1015559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy (FDA approved in adults); has also been used in treatment of McCune-Albright Syndrome (MAS) in girls associated with progressive precocious puberty",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F174722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Ischemic disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flushes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, nausea, vomiting, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, bone pain, extremity pain, joint disorders, musculoskeletal pain, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening (reported with 250 mg or 500 mg dose): Angioedema, hepatitis, hypersensitivity reactions, leukopenia, liver failure, osteoporosis, thrombosis, vaginal bleeding",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1015566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fulvestrant or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F15952567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Use with caution in patients with hepatic impairment; dosage adjustment is recommended in moderate impairment; safety and efficacy have not been established in severe impairment. Use with caution in patients with a history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy; bleeding/hematoma may occur from I.M. administration.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1015567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . May cause fetal harm if administered during pregnancy; women of childbearing potential should be advised to avoid becoming pregnant during therapy; if pregnancy occurs during therapy, patient should be counseled regarding potential fetal hazards. Injectable solution contains benzyl alcohol which may cause allergic reactions in susceptible individuals; may contain ethanol  (10%, w/v) and castor oil.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F1015578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F174674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F174676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F174686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fetal loss and abnormalities were observed in animal studies. Approved for use only in postmenopausal women. If used prior to confirmed menopause, women of reproductive potential should be advised not to become pregnant.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15952569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     McCune-Albright syndrome: In the pediatric clinical trial (study duration: 12 months), the following were monitored: Serum estradiol, testosterone, LH, and FSH (baseline, and at 3, 6, 12 months of therapy); liver function test (baseline and at 12 months of therapy); CBC and INR at baseline; assessments of puberty status and growth at baseline and periodically during therapy [6 and 12 months: Height, weight, Tanner stage, bone age (radiographs), vaginal bleeding data, and  pelvic ultrasounds] (Sims, 2012)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1015581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Estrogen receptor antagonist; competitively binds to estrogen receptors on tumors and other tissue targets, producing a nuclear complex that causes a dose-related down-regulation of estrogen receptors and inhibits tumor growth.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F15952568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Duration: I.M.: Steady state concentrations reached within first month, when administered with additional dose given 2 weeks following the initial dose; plasma levels maintained for at least 1 month",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1015583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~3-5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99%; to plasma proteins (VLDL, LDL, and HDL lipoprotein fractions)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via multiple biotransformation pathways (CYP3A4 substrate involved in oxidation pathway, although relative contribution to metabolism unknown); metabolites formed are either less active or have similar activity to parent compound",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 1-10 years: 70.4 days  (Sims, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 250 mg: ~40 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (~90%); urine (&lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Children 1-8 years: Decreased by 32% compared to adults",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1015600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/8/11396?source=see_link\">",
"      see \"Fulvestrant: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Medication is administered by injection; report immediately any redness, swelling, burning, or pain at injection site. May cause bone or muscle pain, back pain, or headache; nausea, vomiting, or loss of appetite; dizziness; or hot flashes. Report any chest pain or palpitations, swelling of extremities or weight gain, cough, or respiratory difficulty.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sims EK, Garnett S, Guzman F, et al, \"Fulvestrant Treatment of Precocious Puberty in Girls With McCune-Albright Syndrome,\"",
"      <i>",
"       Int J Pediatr Endocrinol",
"      </i>",
"      , 2012, 2012(1):26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/21/2388/abstract-text/22999294/pubmed\" id=\"22999294\" target=\"_blank\">",
"        22999294",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87808 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.117.136.88-C2C11C53A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_21_2388=[""].join("\n");
var outline_f2_21_2388=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174701\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12817149\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1015558\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1015592\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174679\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174667\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1015596\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1015579\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1015559\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174722\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1015566\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15952567\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1015567\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1015578\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174674\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174676\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174686\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15952569\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1015581\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15952568\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1015583\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1015600\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/87808\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/87808|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4964?source=related_link\">",
"      Fulvestrant: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/8/11396?source=related_link\">",
"      Fulvestrant: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_21_2389="Clindamycin (topical): Patient drug information";
var content_f2_21_2389=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Clindamycin (topical): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/46/5862?source=see_link\">",
"     see \"Clindamycin (topical): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/21/38229?source=see_link\">",
"     see \"Clindamycin (topical): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8008024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cleocin T&reg;;",
"     </li>",
"     <li>",
"      Cleocin&reg;;",
"     </li>",
"     <li>",
"      Cleocin&reg; Vaginal Ovule;",
"     </li>",
"     <li>",
"      Clindagel&reg;;",
"     </li>",
"     <li>",
"      ClindaMax&reg;;",
"     </li>",
"     <li>",
"      Clindesse&reg;;",
"     </li>",
"     <li>",
"      Evoclin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8008025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Clinda-T;",
"     </li>",
"     <li>",
"      Clindasol&trade;;",
"     </li>",
"     <li>",
"      Clindets;",
"     </li>",
"     <li>",
"      Dalacin&reg; T;",
"     </li>",
"     <li>",
"      Dalacin&reg; Vaginal;",
"     </li>",
"     <li>",
"      Taro-Clindamycin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691487",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701824",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to clindamycin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: History of very loose stools called pseudomembranous colitis or ulcerative colitis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696724",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Condoms or diaphragms may not work to stop pregnancy. Use some other kind of birth control while taking this drug and for 72 hours after care ends.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaginal irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699053",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad vaginal irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake lotion well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695577",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take pledget out of foil. Use once and throw away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694455",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put foam onto a cool surface or into a cap. Do not place foam in your hands.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705579",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Vaginal:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696196",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use suppository or cream vaginally.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695567",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take off foil wrapper.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696168",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694720",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not have sex while using this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699260",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect foam from heat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11605 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-88.81.100.162-2094B74F85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_21_2389=[""].join("\n");
var outline_f2_21_2389=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008024\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008025\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030413\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030412\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030417\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030418\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030420\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030415\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030416\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030421\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030422\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/46/41704?source=related_link\">",
"      Clindamycin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/49/35604?source=related_link\">",
"      Clindamycin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/1/8215?source=related_link\">",
"      Clindamycin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/46/5862?source=related_link\">",
"      Clindamycin (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/21/38229?source=related_link\">",
"      Clindamycin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_21_2390="Anatomy of the thoracic esophagus posterior";
var content_f2_21_2390=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F70566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F70566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 503px\">",
"   <div class=\"ttl\">",
"    Anatomy of the thoracic esophagus - posterior view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 483px; height: 581px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_21_2390=[""].join("\n");
var outline_f2_21_2390=null;
var title_f2_21_2391="Invade panc duct adenoCA";
var content_f2_21_2391=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F55383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F55383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancreatic ductal adenocarcinoma with duodenal submucosa and muscularis invasion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 261px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pancreatic ductal adenocarcinoma invading the duodenal submucosa (top) and muscularis (bottom). Duodenal mucosa is shown at top right. The carcinoma is moderately differentiated (Grade 2). Hematoxylin and Eosin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel S Longnecker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_21_2391=[""].join("\n");
var outline_f2_21_2391=null;
var title_f2_21_2392="Allergic reactions to seminal plasma";
var content_f2_21_2392=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Allergic reactions to seminal plasma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/21/2392/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/21/2392/contributors\">",
"     David I Bernstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/21/2392/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/21/2392/contributors\">",
"     F Estelle R Simons, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/21/2392/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/21/2392/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/21/2392/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H17329303\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term human seminal plasma refers to the components of human semen other than spermatozoa. Allergic reactions to proteins in human seminal plasma (HSP) usually present as either systemic or localized vaginal reactions beginning, during, or following vaginal sexual intercourse, which are prevented by condom use. The clinical manifestations, epidemiology, pathophysiology, diagnosis, and management of HSP allergy will be discussed in this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23477746\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic reactions to human seminal plasma (HSP) proteins present either as localized vaginal reactions or as systemic allergic",
"    <span class=\"nowrap\">",
"     reactions/anaphylaxis.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17329331\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    largest review of published cases included 74 women; 70 percent (52 patients) experienced systemic symptoms. Forty percent of those with systemic reactions also had local reactions, whereas approximately one-third of patients had",
"    <strong>",
"     only",
"    </strong>",
"    local reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/1\">",
"     1",
"    </a>",
"    ]. All types of reactions are prevented by the use of condoms, which is a critical component of the clinical history. (See",
"    <a class=\"local\" href=\"#H621608421\">",
"     'Clinical history'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29595059\">",
"    <span class=\"h3\">",
"     Systemic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylactic reactions to HSP typically begin within minutes after ejaculation. Initial symptoms commonly include localized vulvar and vaginal pruritus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    edema, followed by diffuse pruritus, nasal obstruction, itching eyes, urticaria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angioedema often involving the face, lips, tongue, and throat. Gastrointestinal symptoms and respiratory symptoms of dyspnea, wheezing, and stridor have also been reported during systemic reactions. Life-threatening anaphylaxis with profound hypotension and cardiovascular collapse, requiring emergency treatment, was reported in 16 patients in the series of 74 women mentioned previously, indicating that severe reactions are not characteristic [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/1\">",
"     1",
"    </a>",
"    ]. No anaphylactic deaths attributable to HSP allergy have been confirmed [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to immediate-type systemic reactions, there are case reports of a patient presenting with a fixed cutaneous eruption [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/2\">",
"     2",
"    </a>",
"    ] and a serum sickness-like reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/3\">",
"     3",
"    </a>",
"    ]. Another uncommon reaction is worsening of preexisting eczema during the days following HSP anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29595069\">",
"    <span class=\"h3\">",
"     Local reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local vaginal reactions to seminal plasma are manifested by vulvar or vaginal pain, itching, burning, and edema [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/1\">",
"     1",
"    </a>",
"    ]. Symptoms and signs may begin immediately following ejaculation or may be delayed in onset by minutes to hours. Vulvar and vaginal discomfort can last several days [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An immediate-onset pruritic rash accompanied by periorbital angioedema was reported in one case after cutaneous exposure to HSP, without any history of vaginal intercourse, suggesting that the skin could be an important route of sensitization [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/6\">",
"     6",
"    </a>",
"    ]. Localized urticaria or eczema has been reported following contact of the skin with HSP [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/7\">",
"     7",
"    </a>",
"    ]. Symptoms from oral contact have not been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17329338\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the large series already described, 87 percent of allergic reactions began within the first 30 minutes following ejaculation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/1\">",
"     1",
"    </a>",
"    ]. This time course is consistent with an immediate-type allergic reaction (ie, beginning within an hour of exposure to the allergen). Symptoms usually resolved within 24 hours, although some symptoms (ie, vaginal pain, recurrent urticaria, and malaise), lingered for days to weeks.",
"   </p>",
"   <p>",
"    Late onset reactions, most of which were systemic reactions, accounted for 13 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/1\">",
"     1",
"    </a>",
"    ]. Time to onset of symptoms ranged from 1 to 15 hours after coitus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H260552860\">",
"    <span class=\"h2\">",
"     Emotional impact",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of HSP hypersensitivity places significant strain on relationships [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, couples present with anxiety about their ability to conceive, although this is usually not a problem if the disorder is managed effectively. (See",
"    <a class=\"local\" href=\"#H285562113\">",
"     'Conception and pregnancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5759455\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly one-half (41 percent) of all HSP allergic reactions occur after a patient&rsquo;s first episode of sexual intercourse. However, anecdotal cases of HSP allergic reactions specific to a certain male partner have been reported in women tolerating intercourse with previous partners [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/8\">",
"     8",
"    </a>",
"    ]. Once HSP allergy has developed, it is usually persistent and continues to occur with the woman&rsquo;s current partner, as well as with future partners [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. There are no known reports of &ldquo;natural tolerance&rdquo; developing with repetitive intercourse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23477754\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSP allergy is seen exclusively in women. Over 60 percent of women presenting with HSP allergy are between the ages of 20 and 30 although new onset symptoms have been reported after age 50 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The general prevalence of seminal plasma allergy is unknown, although it has been described worldwide. There are only about 80 cases of HSP allergic reactions well documented in the medical literature. However, due to the socially sensitive nature of this problem and the broad differential diagnosis of localized reactions, it is likely underreported or mistaken for nonallergic vulvovaginitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A questionnaire survey was conducted to estimate prevalence among 1000 women in North America who voluntarily reported post-coital symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/5\">",
"     5",
"    </a>",
"    ]. In this survey, 266 women reported 130 events (84 systemic and 46 localized). Reactions were classified as \"probable\" HSP hypersensitivity reactions if symptoms were consistently prevented by use of condoms. Skin testing and serum specific IgE were not performed to confirm HSP allergy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17329520\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of other allergic disorders was present in over 80 percent of women with HSP allergy in the large review previously described [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/1\">",
"     1",
"    </a>",
"    ]. Anecdotal reports suggest that adult atopic dermatitis and asthma are common clinical features of women presenting with severe HSP-induced anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/4,10,11\">",
"     4,10,11",
"    </a>",
"    ]. However, HSP anaphylaxis has also been reported in nonatopic women [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon case reports, HSP allergy has been associated with reproductive events or surgical procedures, such as the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Long intercourse-free periods (eg, pregnancy)",
"     </li>",
"     <li>",
"      Menopause",
"     </li>",
"     <li>",
"      Insertion of an intrauterine device",
"     </li>",
"     <li>",
"      Hysterectomy",
"     </li>",
"     <li>",
"      Previous prostatectomy or reversal of vasectomy in the male partner, although the clinical relevance of these procedures is unclear because many women develop HSP allergy with their first intercourse [",
"      <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23477762\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, systemic HSP reactions are caused by a type I, IgE-mediated hypersensitivity reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/1\">",
"     1",
"    </a>",
"    ]. Some, although not all localized immune reactions to HSP are also IgE-mediated [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there is evidence that other immunologic mechanisms can account for some reactions (",
"    <a class=\"graphic graphic_table graphicRef80466 \" href=\"UTD.htm?13/11/13500\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is at least one case report of a delayed-onset systemic reaction consisting of periorbital edema, skin rash, arthralgias, and diarrhea beginning approximately eight hours after ejaculation and lasting four to five days [",
"      <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/3\">",
"       3",
"      </a>",
"      ]. A type III immunologic mechanism was implicated in this serum sickness-like reaction (",
"      <a class=\"graphic graphic_table graphicRef80466 \" href=\"UTD.htm?13/11/13500\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      There is at least one report of a woman with a fixed cutaneous reaction [",
"      <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some local reactions and delayed systemic reactions may represent type IV, T cell mediated reactions [",
"      <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/14,16\">",
"       14,16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H621609142\">",
"    <span class=\"h2\">",
"     Allergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple allergenic proteins with molecular weights ranging from 12 to 75 kDa have been identified in human seminal plasma (HSP) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/1,9,17\">",
"     1,9,17",
"    </a>",
"    ]. In one case report, serum specific IgE binding to a 33 kD protein with a molecular weight identical to prostate specific antigen (PSA) was demonstrated in a patient with HSP anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/18\">",
"     18",
"    </a>",
"    ]. In contrast, sperm proteins have not been implicated as allergens, and artificial insemination using sperm intensively washed free of HSP is well tolerated in women with severe HSP allergy. (See",
"    <a class=\"local\" href=\"#H285562113\">",
"     'Conception and pregnancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The observation that approximately 41 percent of all HSP allergic reactions occur following the first episode of sexual intercourse, suggests that susceptible women can become sensitized prior to their first known contact with human semen [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. The prevalence of HSP-specific IgE in women without HSP allergy has not been studied. There are some data to suggest that sensitization may result from exposure to cross-sensitizing dog proteins, although this is only one theory. In one study, 24 percent of patients with serum specific IgE to dog dander exhibited IgE binding to PSA suggesting existence of cross reactivity between the major HSP allergen and dog epithelial allergens [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/19\">",
"     19",
"    </a>",
"    ]. Prostatic kallikrein is a major dog allergen found in dog urine and epithelium that cross reacts with human PSA [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/20\">",
"     20",
"    </a>",
"    ]. Based on this data, it is possible that women with preexisting dog allergy may be at greater risk for HSP allergy. However, not all women with HSP hypersensitivity are dog owners, although dog allergens are abundant in most indoor environments. At present, there is little utility to evaluating patients for sensitivity to dog allergens, since commercial extracts cannot reliably exclude sensitization to relevant prostatic allergens [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23477778\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H621608421\">",
"    <span class=\"h2\">",
"     Clinical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of localized or systemic reactions following ejaculation and prevented by the use of condoms should prompt evaluation by an allergist with knowledge of the evaluation and management of human seminal plasma (HSP) allergy.",
"   </p>",
"   <p>",
"    The following questions are helpful in determining if a patient&rsquo;s history is consistent with HSP allergy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Do you experience the sensation of vaginal burning during or after ejaculation? If yes, is it prevented by use of a condom?",
"     </li>",
"     <li>",
"      Have you experienced hives, swelling (angioedema), chest tightness, shortness of breath, wheezing, diarrhea, dizziness, or loss of consciousness during or after ejaculation? If yes, is it prevented by use of a condom?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, affected women should be questioned about any latex, food, or medication allergies, and the history explored to determine if a food or drug could have been ingested by the male partner within two to three hours prior to intercourse and passed from the male to the female partner through the ejaculate. (See",
"    <a class=\"local\" href=\"#H23477786\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If not already done, the patient should have a thorough gynecologic evaluation to exclude other causes of vaginal discomfort. (See",
"    <a class=\"local\" href=\"#H23477786\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H621608428\">",
"    <span class=\"h2\">",
"     Objective testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a history suggestive of HSP allergy should be assessed for IgE-mediated allergic sensitization to HSP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1790482\">",
"    <span class=\"h3\">",
"     In vitro testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific IgE assays for seminal plasma are commercially available, but these tests have not been clinically validated. It is the author&rsquo;s experience that these tests are rarely positive, even in patients with HSP anaphylaxis, and a negative test result does not exclude HSP allergy. Therefore, skin testing with whole or fractionated HSP is preferred over serologic testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1790475\">",
"    <span class=\"h3\">",
"     Skin testing with whole seminal plasma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before HSP skin testing is undertaken, the issue of transmission of blood borne illnesses should be addressed with the couple. We generally test the patient&rsquo;s male partner for serologic evidence of active hepatitis A, B, and C, HIV, and syphilis. Testing or treatment procedures should not be performed with HSP from a partner infected with any of these pathogens unless that female partner is also confirmed to be infected and gives consent.",
"   </p>",
"   <p>",
"    The male partner then submits a fresh semen sample, which is allowed to liquefy (ie, sit undisturbed) for 30 minutes at room temperature in a tube. The upper layer (HSP) is used for skin prick testing. If possible, the sample can be centrifuged (as described below) and the supernatant used for testing.",
"   </p>",
"   <p>",
"    Positive (eg, histamine) and negative (saline diluent) controls should be included, as with skin testing to any allergen. The male partner commonly serves as a control and undergoes identical skin tests to exclude the possibility of false positive irritant skin reactions in the female patient. Technical issues related to skin testing are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of skin testing for allergic disease\", section on 'Controls'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1790501\">",
"    <span class=\"h4\">",
"     Interpretation of results",
"    </span>",
"    &nbsp;&mdash;&nbsp;A skin prick test with undiluted whole HSP eliciting a wheal of 3 mm &ge; saline control is positive, confirming HSP allergy. The male partner should have a negative result.",
"   </p>",
"   <p>",
"    If the clinical history is suggestive of HSP hypersensitivity and skin prick testing with whole HSP is negative, it may be a false negative result due to low concentrations of HSP allergens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1790548\">",
"    <span class=\"h2\">",
"     Referral for advanced evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a false negative result is suspected, HSP allergens can be concentrated by column fractionation, which is performed at specialized treatment centers and is relatively costly and labor intensive [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/22\">",
"     22",
"    </a>",
"    ]. However, couples regularly choose to pursue this therapy, and in most cases, they are also planning to undergo subcutaneous immunotherapy to the fractionated HSP preparation.",
"   </p>",
"   <p>",
"    Fractionation requires that multiple ejaculate samples be collected from the male partner. The pooled sample is centrifuged at 1000 g for 30 minutes to separate the spermatozoa from the HSP. The HSP is then run through a column, which isolates those fractions of HSP rich in protein allergens [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/12,21,23\">",
"     12,21,23",
"    </a>",
"    ]. Five or more HSP fractions are typically collected, filter sterilized by syringe through a 0.22 micron filter, and then dialyzed to exclude all materials below 6 to 8000 MW [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/24\">",
"     24",
"    </a>",
"    ]. Prick and intradermal skin testing is performed with each fraction, identifying the allergenic ones. If indicated, HSP immunotherapy may then be performed with one or more allergenic fractions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23477786\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several conditions that should be considered in the differential diagnosis of HSP allergy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vulvodynia (aka, vulvar vestibulitis syndrome) is a condition of chronic pain localized to the vulva or vestibule and triggered by vulvar penetration or physical activity. The clinical manifestations of vulvodynia and local HSP hypersensitivity overlap. HSP allergy has been confirmed in a subset of patients diagnosed with vulvodynia. Serum specific IgE bound to seminal plasma was reported in 50 percent of vulvodynia patients reporting pain exclusively during or after coitus and prevented by condoms [",
"      <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/15,25\">",
"       15,25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23128?source=see_link\">",
"       \"Differential diagnosis of sexual pain in women\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/46/37609?source=see_link\">",
"       \"Clinical manifestations and diagnosis of localized, provoked vulvodynia (formerly vulvar vestibulitis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other gynecological conditions that can be confused with localized HSP allergy include chronic vulvovaginal candidiasis and dyspareunia [",
"      <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/1\">",
"       1",
"      </a>",
"      ]. These conditions are not prevented by use of condoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15386?source=see_link\">",
"       \"Candida vulvovaginitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Local allergic or irritant contact reactions may be attributed to lubricants, spermicides, vaginal contraceptives, or local anesthetics used in latex condoms, non-latex condoms, and other barrier devices. Couples may have tried various barrier devices and found some are tolerated while others are not. If necessary, patch testing can be performed to identify a device that does not cause contact reactions.",
"     </li>",
"     <li>",
"      Exercise induced bronchoconstriction (EIB) or post-coital asthma triggered by sexual intercourse can be confused with HSP-induced anaphylaxis. However, use of a condom does not prevent EIB. Patients suspected of having EIB can be instructed to use an inhaled bronchodilator 10 minutes before intercourse, which should partially or completely prevent symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=see_link&amp;anchor=H4#H4\">",
"       \"Exercise-induced bronchoconstriction\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Natural rubber latex allergy (latex allergy) can cause localized or systemic allergic reactions when latex condoms are used. If symptoms occur when latex condoms are used, a leak in the condom product must be excluded. If this cannot be excluded, non-latex condoms should be tried. The patient should be informed that non-latex condoms may not effectively prevent HIV transmission. When latex allergy is suspected, evaluation should be conducted with US Food and Drug Administration (FDA)-cleared specific IgE immunoassays",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      skin prick testing with latex extract provided a suitable skin test reagent is available. Concurrent sensitization to both latex and HSP has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/26\">",
"       26",
"      </a>",
"      ]. The evaluation and diagnosis of latex allergy is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9785?source=see_link\">",
"       \"Latex allergy: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women with preexisting anaphylactic sensitivity to specific drug (penicillin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ) or food allergens (walnuts) have been reported to experience local or systemic allergic reactions triggered by coital exposure to those drugs or foods ingested by the male partner shortly prior to intercourse [",
"      <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/1,27,28\">",
"       1,27,28",
"      </a>",
"      ]. In such cases, reactions only occur when the male partner ingests the allergenic food or drug, or receives in a period of hours to a day before intercourse. With some medications (eg, chemotherapy), the medication may be present in the male partner&rsquo;s body for several days, which must be considered when evaluating the temporal pattern of reactions. In either scenario, allergic reactions with intercourse do not occur consistently. Sensitization to suspected allergens should be confirmed in female patients with appropriate tests. Unprotected sexual intercourse can be resumed safely as long as the causative allergen is avoided by the male partner for several days prior to sexual intercourse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23477794\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management options include condom use, prophylactic medications taken prior to intercourse, and various types of desensitization therapy. Coitus interruptus is another possible strategy, although most couples find this impractical [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1790619\">",
"    <span class=\"h2\">",
"     Epinephrine for anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An epinephrine autoinjector should be prescribed for patients with previous systemic allergic reactions to HSP and they should be counseled in how and when to self-inject epinephrine. Detailed information for providers and patients is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23832?source=see_link\">",
"     \"Prescribing epinephrine for anaphylaxis self-treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?28/57/29586?source=see_link\">",
"     \"Patient information: Epinephrine auto-injectors (The Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?27/30/28134?source=see_link\">",
"     \"Patient information: Use of an epinephrine autoinjector (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17329632\">",
"    <span class=\"h2\">",
"     Condoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of exposure to HSP allergens and subsequent local and systemic allergic reactions is most easily accomplished by regular use of condoms, which should be put on early in intercourse to avoid contact between the vaginal tissues and pre-ejaculate (as well as ejaculate).",
"   </p>",
"   <p>",
"    However, this approach does not address the risks of HSP reactions occurring as a result of a leaking or defective condom. In addition, condom use does not meet the needs of couples who wish to conceive naturally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17329639\">",
"    <span class=\"h2\">",
"     Prophylactic antihistamines and cromolyn",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a case report, premedication with antihistamines was effective in preventing mild post-coital systemic urticarial reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/10\">",
"     10",
"    </a>",
"    ]. However, antihistamine pretreatment has not been demonstrated to be effective in preventing HSP anaphylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28170123\">",
"    <span class=\"h2\">",
"     Prevention of localized reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are warned that unprotected intercourse without condoms can lead to more severe localized or systemic reactions. Intravaginal cromoglycate has been used prior to intercourse to prevent localized vaginal reactions, with inconsistent results [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/1\">",
"     1",
"    </a>",
"    ]. Other than using condoms, immunotherapy with HSP is the only known effective treatment for preventing localized allergic reactions during intercourse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H285562113\">",
"    <span class=\"h2\">",
"     Conception and pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two approaches to conception are described in women with HSP allergy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravaginal or subcutaneous desensitization, after which couples can conceive naturally. Uncomplicated pregnancies and births have been consistently achieved in this manner [",
"      <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. Desensitization is described in the next section.",
"     </li>",
"     <li>",
"      Artificial insemination with sperm extensively washed free of HSP has also been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/9,32\">",
"       9,32",
"      </a>",
"      ]. HSP-allergic women have tolerated such procedures well, without local or systemic reactions. However, this approach does not allow for natural conception.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17329646\">",
"    <span class=\"h2\">",
"     Desensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desensitization through immunotherapy with HSP may be considered for those patients who find condom use unacceptable or for those wishing to conceive naturally. Both intravaginal and subcutaneous routes of HSP immunotherapy have been successful. These procedures should only be performed in a clinical facility that is fully equipped and adequately staffed for treating anaphylaxis.",
"   </p>",
"   <p>",
"    Following successful desensitization, the patient can tolerate unprotected sexual intercourse with her male partner. However, the couple must have unprotected intercourse two to three times weekly to maintain the desensitized state.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H621609003\">",
"    <span class=\"h3\">",
"     Intravaginal",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several case reports of intravaginal desensitization using the male partner&rsquo;s semen [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/29,30,33,34\">",
"     29,30,33,34",
"    </a>",
"    ]. Intravaginal desensitization has advantages over injection therapy in that it does not require a laboratory or incur the significant costs associated with collection, preparation, and analysis of HSP fractions. However, this approach is not uniformly successful in preventing reactions during intercourse. Based upon the author&rsquo;s experience, many patients referred for subcutaneous desensitization have failed intravaginal protocols. No published series are available to provide estimates of the success of this approach.",
"   </p>",
"   <p>",
"    Intravaginal immunotherapy is performed with whole seminal fluid. In one case report, the procedure was initiated with the intravaginal deposition of 2 mL of 1:1 million dilution of seminal fluid in normal saline [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/31\">",
"     31",
"    </a>",
"    ]. Increasing 10-fold concentrations were then given every 45 minutes, until a dose of undiluted semen was deposited (ie, a 7-step protocol).",
"   </p>",
"   <p>",
"    Unprotected sexual intercourse needs to be repeated two to three times weekly to maintain the desensitized state, as mentioned previously. Non-barrier methods should be used for birth control when the couple does not want to conceive. Interruption of regular sexual intercourse can result in loss of tolerance and recurrence of post-coital allergic reactions. Therefore, if one partner must travel for a period of time, semen can be collected in advance, refrigerated, and inserted intravaginally every three days to maintain tolerance.",
"   </p>",
"   <p>",
"    If intravaginal desensitization is not successful and the couple wishes to conceive naturally, referral for subcutaneous desensitization with fractionated HSP should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/35\">",
"     35",
"    </a>",
"    ]. The other alternative for conception is artificial insemination. (See",
"    <a class=\"local\" href=\"#H285562113\">",
"     'Conception and pregnancy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1790358\">",
"    <span class=\"h3\">",
"     Subcutaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1984, subcutaneous immunotherapy (SCIT) was performed successfully in a woman with seminal plasma anaphylaxis using HSP fractions isolated from pooled samples of the male partner&rsquo;s ejaculate [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/23\">",
"     23",
"    </a>",
"    ]. The HSP fraction was selected based on its ability to elicit a positive intradermal test and induce histamine release from the patient&rsquo;s basophils.",
"   </p>",
"   <p>",
"    A rapid two-day SCIT protocol with HSP fractions has been used successfully in treating patients with IgE mediated localized and systemic HSP reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/12,24\">",
"     12,24",
"    </a>",
"    ]. The author&rsquo;s clinic has successfully desensitized approximately 23 patients. Treated women have tolerated unprotected sexual intercourse as long as it takes place regularly at least two or three times weekly [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2392/abstract/23\">",
"     23",
"    </a>",
"    ]. In the author&rsquo;s experience, couples are generally successful with this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23477802\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergic reactions to human seminal plasma (HSP) may present with either localized vaginal reactions, systemic allergic reactions (including anaphylaxis), or both. The signs and symptoms begin after ejaculation, typically during or immediately following the completion of coitus. Symptoms are prevented by the use of condoms, which is an important piece of the clinical history. (See",
"      <a class=\"local\" href=\"#H23477746\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HSP allergy is rare, although it may be underreported because of the socially sensitive nature of the problem, or misdiagnosed as vulvovaginitis. The disorder occurs exclusively in women, most typically between the ages of 20 and 30 years of age. Once established, it usually occurs with other male partners and is persistent in the absence of desensitization therapy. (See",
"      <a class=\"local\" href=\"#H23477754\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of HSP allergy should be suspected based upon the clinical history, combined with the demonstration of sensitization to HSP by skin testing with whole seminal plasma or allergen-containing fractions of HSP. (See",
"      <a class=\"local\" href=\"#H23477778\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis includes reactions to other allergens (eg, latex) or substances applied to the vaginal area, exertion-related disorders (eg, exercise-induced bronchospasm), and the various disorders that present as vulvodynia and dyspareunia. (See",
"      <a class=\"local\" href=\"#H23477786\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Any woman who has experienced anaphylaxis due to HSP allergy should have an epinephrine autoinjector prescribed and should be counseled regarding how and when to self-inject epinephrine. (See",
"      <a class=\"local\" href=\"#H1790619\">",
"       'Epinephrine for anaphylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who do not wish to conceive and do not object to regular condom use, we suggest avoidance of HSP exposure through careful use of condoms (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This approach to management is simple, although there is some risk to the patient if a condom leaks or breaks. (See",
"      <a class=\"local\" href=\"#H17329632\">",
"       'Condoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who find condom use unacceptable or wish to conceive naturally, we suggest HSP desensitization (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Desensitization can be accomplished using either intravaginal or subcutaneous protocols. (See",
"      <a class=\"local\" href=\"#H17329646\">",
"       'Desensitization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Artificial insemination with sperm washed free of HSP is another approach to conception that is well tolerated by women with HSP hypersensitivity. (See",
"      <a class=\"local\" href=\"#H285562113\">",
"       'Conception and pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/1\">",
"      Shah A, Panjabi C. Human seminal plasma allergy: a review of a rare phenomenon. Clin Exp Allergy 2004; 34:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/2\">",
"      Best CL, Walters C, Adelman DC. Fixed cutaneous eruptions to seminal-plasma challenge: a case report. Fertil Steril 1988; 50:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/3\">",
"      Mike N, Bird G, Asquith P. A new manifestation of seminal fluid hypersensitivity. Q J Med 1990; 75:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/4\">",
"      Mathias CG, Frick OL, Caldwell TM, et al. Immediate hypersensitivity to seminal fluid and atopic dermatitis. Arch Dermatol 1980; 116:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/5\">",
"      Bernstein JA, Sugumaran R, Bernstein DI, Bernstein IL. Prevalence of human seminal plasma hypersensitivity among symptomatic women. Ann Allergy Asthma Immunol 1997; 78:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/6\">",
"      Ohman JL Jr, Malkiel S, Lewis S, Lorusso JR. Allergy to human seminal fluid: characterization of the allergen and experience with immunotherapy. J Allergy Clin Immunol 1990; 85:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/7\">",
"      Bajardeen B, Melendez J, Yoong W. Human seminal plasma hypersensitivity: an unusual indication for in vitro fertilization. Eur J Obstet Gynecol Reprod Biol 2010; 153:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/8\">",
"      Ebo DG, Stevens WJ, Bridts CH, De Clerck LS. Human seminal plasma anaphylaxis (HSPA): case report and literature review. Allergy 1995; 50:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/9\">",
"      Ferr&eacute;-Ybarz L, Basaga&ntilde;a M, Coroleu B, et al. Human seminal plasma allergy and successful pregnancy. J Investig Allergol Clin Immunol 2006; 16:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/10\">",
"      Song WJ, Kim DI, Kim MH, et al. Human seminal plasma allergy: successful pregnancy after prophylactic anti-histamine treatment. Asia Pac Allergy 2011; 1:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/11\">",
"      Nist GC, von den Driesch P. Human seminal plasma allergy--a rare cause of recurrent anaphylaxis. J Dtsch Dermatol Ges 2007; 5:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/12\">",
"      Mittman RJ, Bernstein DI, Adler TR, et al. Selective desensitization to seminal plasma protein fractions after immunotherapy for postcoital anaphylaxis. J Allergy Clin Immunol 1990; 86:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/13\">",
"      Frisch C, Pujade-Lauraine MD, Leynadier F, Dry J. Rush hyposensitisation for allergy to seminal plasma. Lancet 1984; 1:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/14\">",
"      Bernstein IL, Englander BE, Gallagher JS, et al. Localized and systemic hypersensitivity reactions to human seminal fluid. Ann Intern Med 1981; 94:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/15\">",
"      Chang TW. Familial allergic seminal vulvovaginitis. Am J Obstet Gynecol 1976; 126:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/16\">",
"      Kint B, Degreef H, Dooms-Goossens A. Combined allergy to human seminal plasma and latex: case report and review of the literature. Contact Dermatitis 1994; 30:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/17\">",
"      Levine BB, Siraganian RP, Schenkein I. Allergy to human seminal plasma. N Engl J Med 1973; 288:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/18\">",
"      Weidinger S, Mayerhofer A, Raemsch R, et al. Prostate-specific antigen as allergen in human seminal plasma allergy. J Allergy Clin Immunol 2006; 117:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/19\">",
"      Basaga&ntilde;a M, Bartolom&eacute; B, Pastor C, et al. Allergy to human seminal fluid: cross-reactivity with dog dander. J Allergy Clin Immunol 2008; 121:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/20\">",
"      Mattsson L, Lundgren T, Everberg H, et al. Prostatic kallikrein: a new major dog allergen. J Allergy Clin Immunol 2009; 123:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/21\">",
"      Bernstein JA. Human seminal plasma hypersensitivity: an under-recognized women's health issue. Postgrad Med 2011; 123:120.",
"     </a>",
"    </li>",
"    <li>",
"     The author's program, which is based at the University of Cincinnati College of Medicine, in Cincinnati, Ohio, can be accessed at the URL provided. The author is not aware of other centers in the United States that perform HSP fractionation and subcutaneous immunotherapy. www.Seminalplasmaallergy.org (Accessed on April 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/23\">",
"      Friedman SA, Bernstein IL, Enrione M, Marcus ZH. Successful long-term immunotherapy for human seminal plasma anaphylaxis. JAMA 1984; 251:2684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/24\">",
"      Bernstein JA, Herd ZA, Bernstein DI, et al. Evaluation and treatment of localized vaginal immunoglobulin E-mediated hypersensitivity to human seminal plasma. Obstet Gynecol 1993; 82:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/25\">",
"      Babula O, Bongiovanni AM, Ledger WJ, Witkin SS. Immunoglobulin E antibodies to seminal fluid in women with vulvar vestibulitis syndrome: relation to onset and timing of symptoms. Am J Obstet Gynecol 2004; 190:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/26\">",
"      Yocum MW, Jones RT, Yunginger JW. Concurrent sensitization to natural rubber latex and human seminal fluid. J Allergy Clin Immunol 1996; 98:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/27\">",
"      Green RL, Green MA. Postcoital urticaria in a penicillin-sensitive patient. Possible seminal transfer of penicillin. JAMA 1985; 254:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/28\">",
"      Paladine WJ, Cunningham TJ, Donavan MA, Dumper CW. Letter: Possible sensitivity to vinblastine in prostatic or seminal fluid. N Engl J Med 1975; 292:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/29\">",
"      Lee-Wong M, Collins JS, Nozad C, Resnick DJ. Diagnosis and treatment of human seminal plasma hypersensitivity. Obstet Gynecol 2008; 111:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/30\">",
"      Jedrzejczak P, Pawelczyk L. [Pregnancy in a patient with seminal hypersensitivity]. Ginekol Pol 2007; 78:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/31\">",
"      Park JW, Ko SH, Kim CW, et al. Seminal plasma anaphylaxis: successful pregnancy after intravaginal desensitization and immunodetection of allergens. Allergy 1999; 54:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/32\">",
"      Iwahashi K, Miyazaki T, Kuji N, Yoshimura Y. Successful pregnancy in a woman with a human seminal plasma allergy. A case report. J Reprod Med 1999; 44:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/33\">",
"      Lee J, Kim S, Kim M, et al. Anaphylaxis to husband's seminal plasma and treatment by local desensitization. Clin Mol Allergy 2008; 6:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2392/abstract/34\">",
"      Matloff SM. Local intravaginal desensitization to seminal fluid. J Allergy Clin Immunol 1993; 91:1230.",
"     </a>",
"    </li>",
"    <li>",
"     The author's program for HSP fractionation and desensitization can be accessed through the website listed. The program is based at the University of Cincinnati College of Medicine, Cincinnati, Ohio. The author is not aware of other centers in the United States that have published experience in fractionating HSP. Seminalplasmaallergy.org (Accessed on April 01, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13529 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.146-1B4384F6EC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_21_2392=[""].join("\n");
var outline_f2_21_2392=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23477802\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17329303\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23477746\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17329331\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29595059\">",
"      - Systemic reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29595069\">",
"      - Local reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17329338\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H260552860\">",
"      Emotional impact",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5759455\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23477754\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17329520\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23477762\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H621609142\">",
"      Allergens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23477778\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H621608421\">",
"      Clinical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H621608428\">",
"      Objective testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1790482\">",
"      - In vitro testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1790475\">",
"      - Skin testing with whole seminal plasma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1790501\">",
"      Interpretation of results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1790548\">",
"      Referral for advanced evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23477786\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23477794\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1790619\">",
"      Epinephrine for anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17329632\">",
"      Condoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17329639\">",
"      Prophylactic antihistamines and cromolyn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28170123\">",
"      Prevention of localized reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H285562113\">",
"      Conception and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17329646\">",
"      Desensitization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H621609003\">",
"      - Intravaginal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1790358\">",
"      - Subcutaneous",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23477802\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/13529\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/13529|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/11/13500\" title=\"table 1\">",
"      Types allergic reactions SS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15386?source=related_link\">",
"      Candida vulvovaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/46/37609?source=related_link\">",
"      Clinical manifestations and diagnosis of localized, provoked vulvodynia (formerly vulvar vestibulitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23128?source=related_link\">",
"      Differential diagnosis of sexual pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=related_link\">",
"      Exercise-induced bronchoconstriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9785?source=related_link\">",
"      Latex allergy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/57/29586?source=related_link\">",
"      Patient information: Epinephrine auto-injectors (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/30/28134?source=related_link\">",
"      Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23832?source=related_link\">",
"      Prescribing epinephrine for anaphylaxis self-treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_21_2393="Rabies immune globulin and vaccine";
var content_f2_21_2393=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rabies immune globulin and vaccine",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/21/2393/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/21/2393/contributors\">",
"     Alfred DeMaria, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/21/2393/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/21/2393/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/21/2393/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/21/2393/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/21/2393/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/21/2393/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 3.3 billion people worldwide live in areas where rabies is enzootic [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/1\">",
"     1",
"    </a>",
"    ]. Human mortality from endemic canine rabies in Africa and Asia is estimated to be 55,000",
"    <span class=\"nowrap\">",
"     deaths/year.",
"    </span>",
"    In the United States, there has been an average of two fatal human rabies cases annually since 1980, the majority associated with exposure to bats.",
"   </p>",
"   <p>",
"    Rabies is virtually always fatal, but infection can be prevented with proper wound care and postexposure prophylaxis. Although the incidence of human rabies is very low in the United States, approximately 16,000 to 39,000 cases with contact to potentially rabid animals receive rabies postexposure prophylaxis annually [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/2\">",
"     2",
"    </a>",
"    ]. The estimated annual expenditure for rabies prevention is $584 million; the cost of postexposure prophylaxis with rabies immune globulin and vaccine accounts for almost half of this expenditure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The safety, efficacy, and administration of rabies immune globulin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"     rabies vaccine",
"    </a>",
"    will be reviewed here. Clinical decision-making regarding the necessity for rabies prophylaxis can be complex. This issue and the clinical presentation, diagnosis, and care of the patient with suspected rabies are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20088?source=see_link\">",
"     \"When to use rabies prophylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29624?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rabies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general principles guiding rabies prophylaxis, as derived from the Advisory Committee on Immunization Practices (ACIP) guidelines of the US Centers for Disease Control and Prevention (CDC), are discussed below [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/3\">",
"     3",
"    </a>",
"    ]. The full set of guidelines can be accessed at:",
"    <a class=\"external\" href=\"file://www.cdc.gov/mmwr/pdf/rr/rr57e507.pdf\">",
"     file://www.cdc.gov/mmwr/pdf/rr/rr57e507.pdf",
"    </a>",
"    (with updated vaccine schedule recommendations at",
"    <a class=\"external\" href=\"file://www.cdc.gov/mmwr/pdf/rr/rr5902.pdf\">",
"     file://www.cdc.gov/mmwr/pdf/rr/rr5902.pdf",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Timing of prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rabies postexposure prophylaxis is an urgent medical intervention and should begin as soon as possible after the presumed exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     What to administer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rabies immunoglobulin is referred to as \"passive immunization\";",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"     rabies vaccine",
"    </a>",
"    is referred to as \"active immunization\". The choice of rabies biologics (eg, vaccine and rabies immunoglobulin) will depend on whether the patient is receiving pre- or postexposure prophylaxis and on the previous immunization history:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vaccine alone is given for preexposure prophylaxis",
"     </li>",
"     <li>",
"      Postexposure rabies prophylaxis, in previously unimmunized persons, should always include both passive and active immunization.",
"     </li>",
"     <li>",
"      Vaccine alone is indicated in persons who have had preexposure prophylaxis with a cell culture vaccine series or who had been vaccinated with other types of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"       rabies vaccine",
"      </a>",
"      with a documented neutralizing antibody response [",
"      <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The preparations available for passive and active immunization are discussed below. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Available preparations for prophylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Wound care",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most important initial steps to prevent rabies is wound care. Thorough washing of bite wounds, scratches, and non-bite exposures with soap and water is recommended, if feasible. When available, a virucidal agent such as povidone-iodine should also be used. In animal studies of rabies, wound cleansing alone reduced the likelihood of rabies up to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other preventive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetanus prophylaxis, as well as antibiotics, should also be considered depending on the type of wound. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link\">",
"     \"Soft tissue infections due to dog and cat bites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     AVAILABLE PREPARATIONS FOR PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two cell culture rabies vaccines and two rabies immune globulin (RIG) products are both approved and available for use in the United States (",
"    <a class=\"graphic graphic_table graphicRef51563 \" href=\"UTD.htm?33/0/33804\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Rabies immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rabies immune globulin (RIG) is derived from pooled plasma samples of hyperimmunized human donors (human RIG; HRIG) or from horses (equine RIG; ERIG). Although both preparations are considered equally potent and effective, only HRIG is recommended for use in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/2\">",
"     2",
"    </a>",
"    ]. Although these products are derived from human donors or horses, they are treated in ways that eliminate infectious agents, and no transmission of infectious agents has yet been documented from either product.",
"   </p>",
"   <p>",
"    The administration of RIG provides immediate virus-neutralizing antibodies until protective antibodies are generated in response to vaccine. HRIG has a half-life of approximately three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/5\">",
"     5",
"    </a>",
"    ]. Two preparations of HRIG are licensed and available in the United States:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HyperRab",
"      <span class=\"nowrap\">",
"       S/D&trade;",
"      </span>",
"      (Talecris Biotherapeutics) 150 International Units",
"      <span class=\"nowrap\">",
"       (IU)/mL",
"      </span>",
"      (2 mL, 10 mL);",
"      <span class=\"nowrap\">",
"       [solvent/detergent",
"      </span>",
"      treated]",
"     </li>",
"     <li>",
"      Imogam&reg; Rabies-HT (sanofi pasteur) 150 International Units",
"      <span class=\"nowrap\">",
"       (IU)/mL",
"      </span>",
"      (2 mL, 10 mL); [heat treated]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Outside of the US",
"    </span>",
"    &nbsp;&mdash;&nbsp;HRIG is also available outside the United States under a variety of trade names including: Bayrab&reg;, Berirab&reg; P, Imogam&reg;, Imogam&reg; Rabies. Since imported HRIG is expensive and generic products (made in some blood banks abroad) are in scarce supply, ERIG is a commonly used less expensive, but safe and effective, alternative for rabies prophylaxis in resource-limited settings [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Some ERIG is available in a more purified form consisting of immunoglobulin cleavage fragments that are more rapidly cleared after administration; this formulation is also less expensive than HRIG and is safe and effective [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/1\">",
"     1",
"    </a>",
"    ]. During the past two decades, several major manufacturers have discontinued ERIG production because of production costs, pressures from animal rights activists, and more requirements from national regulatory authorities [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of ERIG products can be associated with hypersensitivity reactions and should be administered under close supervision in medical facilities [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Rabies vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"     Rabies vaccine",
"    </a>",
"    induces the production of protective virus-neutralizing antibodies within approximately 7 to 10 days that persist for several years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Two licensed vaccines are currently available in the United States:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Human diploid cell vaccine (HDCV, Imovax&reg; Rabies, Sanofi Pasteur)",
"     </li>",
"     <li>",
"      Purified chick embryo cell vaccine (PCECV, RabAvert&trade;, Novartis Vaccine and Diagnostics)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Either is administered intramuscularly (IM) in doses of 1 mL according to the recommended schedules for pre- or postexposure prophylaxis. A dose of HDCV or PCECV has equal or greater potency to the World Health Organization (WHO) recommended standard of 2.5 IU dose of vaccine.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"     Rabies vaccine",
"    </a>",
"    adsorbed (RVA, Bioport Corporation) is no longer available for rabies postexposure prophylaxis or pre-exposure prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/2\">",
"     2",
"    </a>",
"    ]. A formulation of Imovax rabies vaccine, which had been approved for intradermal administration for preexposure prophylaxis, is also no longer available in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Outside the US",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rabies vaccines available outside the United States include: PCECV (Rabipur&reg;; Chiron Behring), HDCV (Rabivac&trade;), purified vero cell",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"     rabies vaccine",
"    </a>",
"    (PVRV; Verorab&trade;; Sanofi Pasteur; Imovax-Rabies Vero&trade;, TRC Verorab&trade;) and purified duck embryo vaccine (Lyssavac N&trade;).",
"   </p>",
"   <p>",
"    In developing countries, HDCV is the most expensive product and has been mainly replaced by less costly cell culture vaccines, such as PVRV or PCECV. These two vaccines are as effective and safe as HDCV [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/6\">",
"     6",
"    </a>",
"    ]. However, given the amount of postexposure treatment needed, the cost of these vaccines is still high for many developing countries. Two reduced dose intradermal regimens for postexposure prophylaxis have been previously recommended by WHO to help contain the cost associated with intramuscular administration [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first regimen is the \"Thai Red Cross\" intradermal schedule (\"2-2-2-0-2\" regimen), which has been proven to be efficacious when given with PVRV or PCECV vaccine. The recommended dose is one injection of 0.1 mL at each side of the upper arm on days 0, 3, 7 and 28.",
"     </li>",
"     <li>",
"      The second regimen is the \"Oxford\" eight-site intradermal schedule (\"8-0-4-0-1-1\" regimen) with either HDCV (0.1 mL) or PCECV (0.1 mL). The schedule includes: day 0, injections at eight sites (one in each upper arm, one in each lateral thigh, one on each side of the suprascapular region, and one on each side of the lower quadrant region of the abdomen); day 7, injections at four sites (each upper arm and each lateral thigh); and days 30 and 90, one injection (upper arm).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the WHO guidelines in 2010 have removed the rarely used eight-site regimen to simplify the use of intradermal postexposure prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of note, the intradermal route is still being used for preexposure prophylaxis in resource-limited settings. The doses and schedules are discussed below. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Dosing schedules and routes of administration'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because of the technical requirements for production and the high cost of vaccines derived from cell culture, vaccines are still produced in sheep, goat, or suckling mouse nervous tissue in some resource-limited countries, although there is an international effort to eliminate such products [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/7\">",
"     7",
"    </a>",
"    ]. These vaccines have unreliable potency and a high incidence of neurological complications [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/11\">",
"     11",
"    </a>",
"    ]. The WHO Expert Committee on Rabies has recommended that all developing countries should replace the nerve tissue-derived vaccines with safer cell culture vaccines. Over the past two decades, many countries have been importing cell culture vaccines, while others are developing better technology for their production.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EFFICACY AND IMMUNOGENICITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Postexposure prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of cell culture",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"     rabies vaccine",
"    </a>",
"    plus RIG in preventing death and eliciting neutralizing antibodies after rabies exposure has been demonstrated in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/2,9,12\">",
"     2,9,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Combination of five IM doses of HDCV and HRIG prophylaxis was evaluated in 90 persons treated after exposure to rabies, 21 of whom were bitten by proven rabid animals [",
"      <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/9\">",
"       9",
"      </a>",
"      ]. All 87 persons tested developed protective titers of antibody (&ge;0.5 international units",
"      <span class=\"nowrap\">",
"       (IU)/mL).",
"      </span>",
"      One year after vaccination, all 33 persons who had follow-up testing had detectable antibodies to rabies virus.",
"     </li>",
"     <li>",
"      Forty-five persons bitten by rabid dogs and wolves in Iran were treated with HDCV and all, except one, also received RIG [",
"      <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/12\">",
"       12",
"      </a>",
"      ]. None of the exposed persons developed rabies.",
"     </li>",
"     <li>",
"      In a series of 40 patients with rabies exposure, all who received HDCV, with or without RIG, seroconverted; however, those who received both had significantly higher rabies antibody titers [",
"      <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study reported no human rabies cases among 45 patients receiving six intramuscular doses of PCECV and HRIG after being exposed to biopsy-proven rabid animals [",
"      <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A Chinese study of 171 patients with severe rabies exposure who received five intramuscular PVRV plus ERIG demonstrated protective neutralizing antibodies of more than 0.5",
"      <span class=\"nowrap\">",
"       IU/mL",
"      </span>",
"      by day 14 in all 171 cases. No one developed rabies up to six months after treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effectiveness of all current cell culture vaccines given intradermally with or without RIG among rabies-exposed humans has been demonstrated in several studies with different schedules [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/16-19\">",
"     16-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Preexposure prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in animals have demonstrated protective levels of antibody after immunization with HDCV [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. One study demonstrated protection against challenge with rabies viruses after primary vaccination with PCECV or HDCV in all animals except in one group that had been challenged through an intracranial route; this group had a 5 percent mortality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple studies in humans demonstrate that vaccination with HDCV or PCECV results in significant titers of neutralizing antibodies by day 14 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. One study of 177 volunteers noted that antibody kinetics and persistence of antibody over two years were similar between the two vaccine preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SAFETY OF RABIES BIOLOGICS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Rabies immunoglobulin (RIG)",
"    </span>",
"    &nbsp;&mdash;&nbsp;HRIG is associated with local reactions including pain and tenderness, erythema, and induration. Headache is the most commonly reported systemic side effect [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective study at the Thai Red Cross, adverse events to HRIG and ERIG were reviewed in more than 70,000 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/26\">",
"     26",
"    </a>",
"    ]. A higher number of side effects occurred among those who had received ERIG (1.83 versus 0.09 percent). General observations also included a higher risk of hypersensitivity to either product among females and a lower risk of serum-sickness in children under 10 years of age. Only one patient developed anaphylaxis associated with ERIG administration.",
"   </p>",
"   <p>",
"    There has never been evidence of transmission of any known virus or infectious agent by HRIG approved for use in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Human diploid cell vaccine (HDCV)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local reactions, including pain at the injection site, redness, swelling, and induration, have been reported in many patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/23,27\">",
"     23,27",
"    </a>",
"    ]. Most are mild and resolve in a few days. Systemic reactions are less common and include mild fever, headache, dizziness, and gastrointestinal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/23,27\">",
"     23,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systemic hypersensitivity reactions have been reported in up to 6 percent of persons receiving a booster vaccination with HDCV following primary rabies prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/28\">",
"     28",
"    </a>",
"    ]. During surveillance for adverse events following HDCV immunization from 1980 to1984, the Centers for Disease Control and Prevention received reports of 108 systemic allergic reactions, ranging from hives to anaphylaxis, for a rate of approximately 11 per 10,000 vaccinees [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/29\">",
"     29",
"    </a>",
"    ]. Clinicians who require assistance in the management of a patient with significant hypersensitivity should contact their state health department or the CDC. All serious vaccine reactions should be reported to the Vaccine Adverse Event Reporting System (VAERS), phone number 800-822-7967. We suggest using the PCECV formulation for future dosing in patients with hypersensitivity. Likewise, although hypersensitivity to PCECV is less well described [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/30\">",
"     30",
"    </a>",
"    ], HDCV vaccine can replace PCECV if hypersensitivity develops with the use of that product as initial vaccine.",
"   </p>",
"   <p>",
"    Rare case reports of neurologic adverse events following rabies vaccination have also been reported; however causality has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Purified chick embryo cell vaccine (PCECV)",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCECV is also associated with local reactions at the injection site [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/30\">",
"     30",
"    </a>",
"    ]. A retrospective review of adverse events following immunization with PCECV was conducted using data from VAERS over an eight-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/31\">",
"     31",
"    </a>",
"    ]. Mild side effects included headache, fever, myalgia, nausea, and weakness. Serious adverse events were uncommon (3 per 100,000 doses distributed).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DOSING SCHEDULES AND ROUTES OF ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rabies postexposure prophylaxis should begin as soon as possible after the exposure. Dosing schedules, dose and route are listed in table (",
"    <a class=\"graphic graphic_table graphicRef70600 \" href=\"UTD.htm?27/43/28347\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Rabies immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, RIG is only given for postexposure prophylaxis. The recommended dose of HRIG in all age groups is 20",
"    <span class=\"nowrap\">",
"     IU/kg",
"    </span>",
"    while the recommended dose of ERIG (including F(ab\")2 products) is 40",
"    <span class=\"nowrap\">",
"     IU/kg",
"    </span>",
"    body weight. RIG can partially suppress antibody production, so no more than the single recommended dose should be administered.",
"   </p>",
"   <p>",
"    RIG should always be given in a different syringe from the vaccine, and at a different intramuscular site, such as the deltoid muscle opposite the vaccine dose or the anterior thigh.",
"   </p>",
"   <p>",
"    As much of the RIG dose as is anatomically feasible should be infiltrated in the area around and in the wounds. Any remaining dose should be given intramuscularly. If there is no obvious wound (eg, suspected bat exposure), the large volume of RIG is best administered into the gluteal muscle. When this area is used for injection, RIG should be administered carefully in the upper outer quadrant of the gluteus to avoid possible damage to the sciatic nerve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Rabies vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"     Rabies vaccine",
"    </a>",
"    is given for pre- or postexposure prophylaxis. The dosing schedule is determined by the intended use (",
"    <a class=\"graphic graphic_table graphicRef74185 \" href=\"UTD.htm?19/38/20075\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Antibody responses in normal volunteers are uniform and relatively long lived. All persons tested during Centers for Disease Control and Prevention (CDC) studies have had adequate titers two to four weeks after completion of the recommended vaccine schedule. Thus, routine testing after preexposure prophylaxis is not recommended.",
"   </p>",
"   <p>",
"    Vaccine should",
"    <strong>",
"     never",
"    </strong>",
"    be administered in the gluteal area, because this may result in lower antibody titers [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/32\">",
"     32",
"    </a>",
"    ]. &nbsp;The deltoid is the only acceptable site of administration in adults and older children, but the outer aspect of the thigh can be used in young children [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Preexposure prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A primary series for preexposure prophylaxis includes three doses of vaccine (",
"    <a class=\"graphic graphic_table graphicRef74185 \" href=\"UTD.htm?19/38/20075\">",
"     table 3",
"    </a>",
"    ). A booster vaccine should be administered to those with ongoing risk when neutralizing antibodies decline to less than protective levels. The minimum acceptable antibody level, as recommended by the CDC, is complete virus neutralization at a 1:5 serum dilution by the rapid fluorescent focus inhibition test (RFFIT). Recommendations for intervals for serologic testing are found in the table (",
"    <a class=\"graphic graphic_table graphicRef61388 \" href=\"UTD.htm?16/6/16492\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Postexposure prophylaxis for unvaccinated persons",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) and Centers for Disease Control (CDC) guidelines vary regarding postexposure prophylaxis in unvaccinated persons.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CDC guidelines for vaccine administration for postexposure prophylaxis in unvaccinated persons exposed to rabies changed in 2010, from a five-dose schedule of vaccine (given intramuscularly) starting immediately (day 0) after exposure and on days 3, 7, 14, and 28 after the first dose to a four-dose schedule eliminating the day 28 dose of the series [",
"      <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. This change was based on the following [",
"      <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/33,35\">",
"       33,35",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Global epidemiologic studies demonstrating that rabies had not developed in any patient who received appropriate wound care, HRIG, and four doses of vaccine",
"     </li>",
"     <li>",
"      Immunogenicity studies showing that the fifth dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"       rabies vaccine",
"      </a>",
"      did not lead to a further increase in antibody titers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the four-dose recommendation is in conflict with the package inserts for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"     rabies vaccine",
"    </a>",
"    from both existing manufacturers (Novartis and Sanofi) that are not expected to change [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The WHO guidelines vary depending on the category of exposure. The WHO guidelines still recommend a five-dose schedule for intramuscular rabies immunization for category 2 or 3 exposures, but now cite the four-dose intramuscular schedule (days 0, 3, 7 and 14) as an alternative for exposed people who receive wound care plus high-quality RIG plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"       rabies vaccine",
"      </a>",
"      (approved by the WHO). Another alternative four-dose regimen (two doses on day 0, and one dose on days 7 and 21) is sometimes used for category 2 exposures, when postexposure treatment does not include administration of RIG. Information on the WHO four-dose regimen (2-1-1) can be accessed at:",
"      <a class=\"external\" href=\"file://www.who.int/rabies/human/postexp/en/index.html\">",
"       www.who.int/rabies/human/postexp/en/index.html",
"      </a>",
"      .",
"      <br/>",
"      <br/>",
"      The WHO classification of rabies exposures is found elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20088?source=see_link&amp;anchor=H22#H22\">",
"       \"When to use rabies prophylaxis\", section on 'Postexposure prophylaxis in resource-limited settings'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, it must be noted that both guidelines recommend the five-dose schedule in immunocompromised hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/1,33\">",
"     1,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Doses should be given in the deltoid via the intramuscular route; in young children the anterolateral thigh is also acceptable.",
"   </p>",
"   <p>",
"    Reducing the number of clinic visits for rabies prophylaxis would help improve completion of postexposure dosing schedules. Preliminary results from one study in healthy volunteers suggest that a one-week schedule of prophylaxis increases neutralizing antibody levels compared with standard regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Postexposure prophylaxis for previously vaccinated persons",
"    </span>",
"    &nbsp;&mdash;&nbsp;A previously vaccinated person who has had a potential rabies exposure should receive two intramuscular doses of vaccine; the first dose should be given on day 0, as soon after exposure as possible, and the other three days later.",
"   </p>",
"   <p>",
"    Individuals who qualify as previously immunized include those who have received one of the vaccines according to either preexposure or postexposure immunization schedules recommended in the United States, or those who had a documented adequate rabies antibody titer following another vaccine product or schedule.",
"   </p>",
"   <p>",
"    It is not necessary to also give RIG because of the anamnestic response to vaccine in persons effectively vaccinated previously. Routine serologic testing after boosting is not recommended because of the uniformity of an antibody response.",
"   </p>",
"   <p>",
"    The WHO guidelines also recommend two alternative intradermal regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One intradermal injection of 0.1 mL",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"       rabies vaccine",
"      </a>",
"      at a single site on days 0 and 3",
"     </li>",
"     <li>",
"      Four intradermal injections of 0.1 mL",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"       rabies vaccine",
"      </a>",
"      in the upper arm or thigh all given on the same day",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     POST VACCINATION SEROLOGIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"     Rabies vaccine",
"    </a>",
"    induces protective neutralizing antibodies in the vast majority of patients; thus, no postvaccination serologic testing is necessary. However, serologic testing may be considered in the immunosuppressed host or in any patient who has had significant deviations from the recommended vaccine schedule. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Deviations from immunization schedules'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H31\">",
"     'Immunosuppression'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     DELAYS IN IMMUNIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rabies postexposure prophylaxis should begin as soon as possible after the exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, no vaccine failures have been reported in the United States, despite an average delay to vaccination of approximately five days [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/38\">",
"     38",
"    </a>",
"    ]. Furthermore, since latency periods between exposure and onset of disease as long as one to over six years have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/39\">",
"     39",
"    </a>",
"    ], postexposure prophylaxis should be given following a rabies exposure, regardless of the length of the delay. Postexposure prophylaxis is never too early and is only too late when signs of clinical rabies are developing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     DEVIATIONS FROM IMMUNIZATION SCHEDULES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most deviations from the immunization schedule do not require complete reinitiation of vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/40\">",
"     40",
"    </a>",
"    ]. If a patient misses an injection, the immunization series should be continued until all doses have been administered. Vaccine should be administered according to the regular intervals (eg, if day 7 vaccine is given on day 10, the next dose should be on day 17, 7 days later, etc.). If there is any concern regarding efficacy, antibody testing can be conducted at or after 14 days and 7 to 14 days after the final dose is given.",
"   </p>",
"   <p>",
"    Although the vaccine formulations are essentially equivalent in immunogenicity, and theoretically can be substituted for one another, there are scant data on this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/41\">",
"     41",
"    </a>",
"    ]. Thus, when feasible, use of the same vaccine formulation is recommended during the entire immunization series.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SPECIAL CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that rabies vaccination is associated with fetal abnormalities of any kind [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Pregnancy is therefore not a contraindication to postexposure prophylaxis if a rabies exposure has occurred. The danger of rabies after a significant exposure far outweighs any theoretical risk from immunization. For patients in a continuous or frequent risk category, preexposure prophylaxis might also be necessary during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Antimalarial prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of case reports of blunted immune response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"     rabies vaccine",
"    </a>",
"    in individuals on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    malarial prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/44\">",
"     44",
"    </a>",
"    ], a randomized controlled study was performed in 51 veterinary students to assess antibody responses to intradermal HDCV when chloroquine was administered [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/44\">",
"     44",
"    </a>",
"    ]. Although all achieved an adequate vaccine response, according to CDC criteria, the mean neutralizing antibody titers were significantly lower in the 26 individuals who also received malaria prophylaxis.",
"   </p>",
"   <p>",
"    Decreased antibody titers have not been documented with other antimalarials (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    ), although it is theoretically possible. The WHO recommends that patients who are receiving antimalarial prophylaxis should be given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"     rabies vaccine",
"    </a>",
"    intramuscularly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/45\">",
"     45",
"    </a>",
"    ], but it is assumed that corticosteroids, other immunosuppressive drugs, and immunocompromising illnesses may prevent the immune response to rabies vaccination to the point of insufficient neutralizing antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/46\">",
"     46",
"    </a>",
"    ]. One small study suggests that HIV-infected patients are among those with suboptimal responses [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/47\">",
"     47",
"    </a>",
"    ]. Ideally, immunosuppressed patients should avoid activities for which rabies preexposure prophylaxis is indicated. If this is not possible, they should be vaccinated by the intramuscular route and their antibody titers checked after completion of immunization.",
"   </p>",
"   <p>",
"    If postexposure prophylaxis is needed in an immunosuppressed person, antibody titers should be measured. Sera should be collected around day 14 of the vaccine series and at the time of completing prophylaxis Failure of response should be managed in consultation with state public health authorities or the CDC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     VACCINE FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Currently recommended postexposure prophylaxis regimens appear uniformly effective. No postexposure vaccine failures have occurred in the United States.",
"   </p>",
"   <p>",
"    The occasional case reports of rabies in vaccinated individuals have occurred abroad in cases where the current recommendations have not been followed [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/2\">",
"     2",
"    </a>",
"    ]. Failure of prophylaxis has been associated with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improper wound cleaning",
"     </li>",
"     <li>",
"      Inadequate dosing of RIG",
"     </li>",
"     <li>",
"      Absence of RIG administration in the wound site",
"     </li>",
"     <li>",
"      Vaccine administration in the gluteal area",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If a postexposure prophylaxis regimen using unknown or non-standard biologics was completed abroad, an antibody titer should be checked. If it is inadequate, postexposure prophylaxis should be readministered in consultation with the state public health department or the CDC. If it is adequate, additional immunization is generally not indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     FUTURE RESEARCH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to a global shortage of HRIG and ERIG, other alternate means of prophylaxis are being sought. Human monoclonal antibodies (CR57 and CR4098) demonstrated in vitro neutralization against rabies virus [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/48\">",
"     48",
"    </a>",
"    ]. In an animal model, these monoclonal antibodies provided a level of protection against lethal rabies virus challenge similar to human RIG.",
"   </p>",
"   <p>",
"    In the first clinical study among healthy adults in the US and India, CR57 and CR4098 were safe and well-tolerated. All subjects had adequate neutralizing activity against rabies virus from day 14 onward when administered in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"     rabies vaccine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2393/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/23/2418?source=see_link\">",
"       \"Patient information: Rabies (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rabies is virtually always fatal, but disease can be prevented with proper wound care and postexposure prophylaxis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rabies postexposure prophylaxis should begin as soon as possible after the presumed exposure. Postexposure rabies prophylaxis in previously unimmunized persons should always include both passive and active immunization. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The administration of rabies immune globulin (RIG) provides immediate virus neutralizing antibodies until protective antibodies are generated in response to vaccine.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"       Rabies vaccine",
"      </a>",
"      induces the production of protective virus neutralizing antibodies within approximately 7 to 10 days that persist for several years. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Available preparations for prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The effectiveness of cell culture",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"       rabies vaccine",
"      </a>",
"      plus RIG in preventing death and eliciting antibodies after rabies exposure has been demonstrated in studies of individuals who had significant bites from rabid animals. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Efficacy and immunogenicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both rabies immunoglobulin and rabies vaccines have been associated with local reactions. Systemic hypersensitivity reactions have been reported in up to 6 percent of persons receiving a booster vaccination with human diploid cell vaccine (HDCV) following primary rabies prophylaxis. In this clinical scenario, further dosing using purified chick embryo cell vaccine may be used. Alternatively HDCV can be substituted for PCECV in the reverse situation. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Safety of rabies biologics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The proper route and sites of administration are important to observe to optimize protective efficacy and prevent vaccine failure. The wound should be infiltrated with RIG; the gluteal muscle should",
"      <strong>",
"       NOT",
"      </strong>",
"      be used for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"       rabies vaccine",
"      </a>",
"      since antibody responses have been lower after administration at that site. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Dosing schedules and routes of administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While rabies postexposure prophylaxis should begin as soon as possible, since long latency periods between exposure and disease have been reported, postexposure prophylaxis should be given following a rabies exposure, regardless of the length of the delay. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Delays in immunization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunization schedules should be adhered to as closely as possible. However, if a delay occurs, the schedule should simply resume with intervals preserved within the new schedule. Antibody titers should be assessed to evaluate efficacy if the dosing schedule has been significantly violated. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Deviations from immunization schedules'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnancy is",
"      <strong>",
"       not",
"      </strong>",
"      a contraindication to postexposure prophylaxis if a rabies exposure has occurred. Antibody titers should be checked in immunosuppressed patients who receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"       rabies vaccine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Special considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vaccine schedules are very effective; vaccine failures have been associated with protocol violations. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Vaccine failure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29251206\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editors of UpToDate, Inc. would like to acknowledge Wichai Techasathit, MD, MPH, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/1\">",
"      WHO Publication. Rabies vaccines: WHO position paper--recommendations. Vaccine 2010; 28:7140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/2\">",
"      Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention--United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2008; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/3\">",
"      Knobel DL, Cleaveland S, Coleman PG, et al. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ 2005; 83:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/4\">",
"      DEAN DJ, BAER GM, THOMPSON WR. Studies on the local treatment of rabies-infected wounds. Bull World Health Organ 1963; 28:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/5\">",
"      Cabasso VJ, Loofbourow JC, Roby RE, Anuskiewicz W. Rabies immune globulin of human origin: preparation and dosage determination in non-exposed volunteer subjects. Bull World Health Organ 1971; 45:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/6\">",
"      Wilde H, Tipkong P, Khawplod P. Economic issues in postexposure rabies treatment. J Travel Med 1999; 6:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/7\">",
"      Chantanakajornfung A, Naraporn N, Khumphai W, et al. A study of human rabies immune globulin manufactured by the Thai Red Cross. Vaccine 1999; 17:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/8\">",
"      Wilde H, Khawplod P, Hemachudha T, Sitprija V. Postexposure treatment of rabies infection: can it be done without immunoglobulin? Clin Infect Dis 2002; 34:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/9\">",
"      Anderson LJ, Sikes RK, Langkop CW, et al. Postexposure trial of a human diploid cell strain rabies vaccine. J Infect Dis 1980; 142:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/10\">",
"      Strady A, Lang J, Lienard M, et al. Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy. J Infect Dis 1998; 177:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/11\">",
"      Hemachudha T, Phanuphak P, Johnson RT, et al. Neurologic complications of Semple-type rabies vaccine: clinical and immunologic studies. Neurology 1987; 37:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/12\">",
"      Bahmanyar M, Fayaz A, Nour-Salehi S, et al. Successful protection of humans exposed to rabies infection. Postexposure treatment with the new human diploid cell rabies vaccine and antirabies serum. JAMA 1976; 236:2751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/13\">",
"      Navarrete-Navarro S, Aguilar-Seti&eacute;n A, Avila-Figueroa C, et al. Improved serological response to human diploid cell rabies vaccine when given simultaneously with antirabies hyperimmune globulin. Arch Med Res 1999; 30:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/14\">",
"      Bijok U, Vodopija I, Smerdel S, et al. Purified chick embryo cell (PCEC) rabies vaccine for human use: clinical trials. Behring Inst Mitt 1984; :155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/15\">",
"      Wang XJ, Lang J, Tao XR, et al. Immunogenicity and safety of purified Vero-cell rabies vaccine in severely rabies-exposed patients in China. Southeast Asian J Trop Med Public Health 2000; 31:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/16\">",
"      Harverson G, Wasi C. Use of post-exposure intradermal rabies vaccination in a rural mission hospital. Lancet 1984; 2:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/17\">",
"      Warrell MJ, Nicholson KG, Warrell DA, et al. Economical multiple-site intradermal immunisation with human diploid-cell-strain vaccine is effective for post-exposure rabies prophylaxis. Lancet 1985; 1:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/18\">",
"      Chutivongse S, Wilde H, Supich C, et al. Postexposure prophylaxis for rabies with antiserum and intradermal vaccination. Lancet 1990; 335:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/19\">",
"      Quiambao BP, Dimaano EM, Ambas C, et al. Reducing the cost of post-exposure rabies prophylaxis: efficacy of 0.1 ml PCEC rabies vaccine administered intradermally using the Thai Red Cross post-exposure regimen in patients severely exposed to laboratory-confirmed rabid animals. Vaccine 2005; 23:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/20\">",
"      Brookes SM, Parsons G, Johnson N, et al. Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses. Vaccine 2005; 23:4101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/21\">",
"      Lodmell DL, Ewalt LC. Rabies vaccination: comparison of neutralizing antibody responses after priming and boosting with different combinations of DNA, inactivated virus, or recombinant vaccinia virus vaccines. Vaccine 2000; 18:2394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/22\">",
"      Fishbein DB, Bernard KW, Miller KD, et al. The early kinetics of the neutralizing antibody response after booster immunizations with human diploid cell rabies vaccine. Am J Trop Med Hyg 1986; 35:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/23\">",
"      Sabchareon A, Lang J, Attanath P, et al. A new Vero cell rabies vaccine: results of a comparative trial with human diploid cell rabies vaccine in children. Clin Infect Dis 1999; 29:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/24\">",
"      Nicholson KG, Farrow PR, Bijok U, Barth R. Pre-exposure studies with purified chick embryo cell culture rabies vaccine and human diploid cell vaccine: serological and clinical responses in man. Vaccine 1987; 5:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/25\">",
"      Lang J, Gravenstein S, Briggs D, et al. Evaluation of the safety and immunogenicity of a new, heat-treated human rabies immune globulin using a sham, post-exposure prophylaxis of rabies. Biologicals 1998; 26:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/26\">",
"      Suwansrinon K, Jaijareonsup W, Wilde H, et al. Sex- and age-related differences in rabies immunoglobulin hypersensitivity. Trans R Soc Trop Med Hyg 2007; 101:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/27\">",
"      Fishbein DB, Dreesen DW, Holmes DF, et al. Human diploid cell rabies vaccine purified by zonal centrifugation: a controlled study of antibody response and side effects following primary and booster pre-exposure immunizations. Vaccine 1989; 7:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/28\">",
"      Fishbein DB, Yenne KM, Dreesen DW, et al. Risk factors for systemic hypersensitivity reactions after booster vaccinations with human diploid cell rabies vaccine: a nationwide prospective study. Vaccine 1993; 11:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/29\">",
"      Centers for Disease Control (CDC). Systemic allergic reactions following immunization with human diploid cell rabies vaccine. MMWR Morb Mortal Wkly Rep 1984; 33:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/30\">",
"      Dreesen DW, Fishbein DB, Kemp DT, Brown J. Two-year comparative trial on the immunogenicity and adverse effects of purified chick embryo cell rabies vaccine for pre-exposure immunization. Vaccine 1989; 7:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/31\">",
"      Dobardzic A, Izurieta H, Woo EJ, et al. Safety review of the purified chick embryo cell rabies vaccine: Data from the Vaccine Adverse Event Reporting System (VAERS), 1997-2005. Vaccine 2007; 25:4244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/32\">",
"      Fishbein DB, Sawyer LA, Reid-Sanden FL, Weir EH. Administration of human diploid-cell rabies vaccine in the gluteal area. N Engl J Med 1988; 318:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/33\">",
"      Rupprecht CE, Briggs D, Brown CM, et al. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/34\">",
"      Committee on Infectious Diseases. Rabies-prevention policy update: new reduced-dose schedule. Pediatrics 2011; 127:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/35\">",
"      Rupprecht CE, Briggs D, Brown CM, et al. Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals. Vaccine 2009; 27:7141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/36\">",
"      Shantavasinkul P, Tantawichien T, Wilde H, et al. Postexposure rabies prophylaxis completed in 1 week: preliminary study. Clin Infect Dis 2010; 50:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/37\">",
"      Uwanyiligira M, Landry P, Genton B, de Valliere S. Rabies postexposure prophylaxis in routine practice in view of the new Centers for Disease Control and Prevention and World Health Organization recommendations. Clin Infect Dis 2012; 55:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/38\">",
"      Human rabies prevention--United States, 1999. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/39\">",
"      Smith JS, Fishbein DB, Rupprecht CE, Clark K. Unexplained rabies in three immigrants in the United States. A virologic investigation. N Engl J Med 1991; 324:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/40\">",
"      Rupprecht CE, Gibbons RV. Clinical practice. Prophylaxis against rabies. N Engl J Med 2004; 351:2626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/41\">",
"      Briggs DJ, Dreesen DW, Nicolay U, et al. Purified Chick Embryo Cell Culture Rabies Vaccine: interchangeability with Human Diploid Cell Culture Rabies Vaccine and comparison of one versus two-dose post-exposure booster regimen for previously immunized persons. Vaccine 2000; 19:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/42\">",
"      Chutivongse S, Wilde H, Benjavongkulchai M, et al. Postexposure rabies vaccination during pregnancy: effect on 202 women and their infants. Clin Infect Dis 1995; 20:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/43\">",
"      Varner MW, McGuinness GA, Galask RP. Rabies vaccination in pregnancy. Am J Obstet Gynecol 1982; 143:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/44\">",
"      Pappaioanou M, Fishbein DB, Dreesen DW, et al. Antibody response to preexposure human diploid-cell rabies vaccine given concurrently with chloroquine. N Engl J Med 1986; 314:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/45\">",
"      Bernard KW, Fishbein DB, Miller KD, et al. Pre-exposure rabies immunization with human diploid cell vaccine: decreased antibody responses in persons immunized in developing countries. Am J Trop Med Hyg 1985; 34:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/46\">",
"      Enright JB, Franti CE, Frye FL, Behymer DE. The effects of corticosteroids on rabies in mice. Can J Microbiol 1970; 16:667.",
"     </a>",
"    </li>",
"    <li>",
"     Deshpande A, Briggs DJ, Dietzschold B et al. Immune response to purified chick embryo cell vaccine (PCECV) in HIV-infected individuals in Mumbai India using a simulated rabies post-exposure regimen. In: Proceedings of the IX International Meeting on Research Advances and Rabies Control in the Americas, Puerto Vallarta Mexico, December 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/48\">",
"      Goudsmit J, Marissen WE, Weldon WC, et al. Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J Infect Dis 2006; 193:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2393/abstract/49\">",
"      Bakker AB, Python C, Kissling CJ, et al. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 2008; 26:5922.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8303 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-EFD95E538C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_21_2393=[""].join("\n");
var outline_f2_21_2393=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Timing of prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      What to administer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Wound care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other preventive care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      AVAILABLE PREPARATIONS FOR PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Rabies immune globulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Outside of the US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Rabies vaccines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Outside the US",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EFFICACY AND IMMUNOGENICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Preexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SAFETY OF RABIES BIOLOGICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Rabies immunoglobulin (RIG)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Human diploid cell vaccine (HDCV)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Purified chick embryo cell vaccine (PCECV)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DOSING SCHEDULES AND ROUTES OF ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Rabies immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Rabies vaccines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Preexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Postexposure prophylaxis for unvaccinated persons",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Postexposure prophylaxis for previously vaccinated persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      POST VACCINATION SEROLOGIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      DELAYS IN IMMUNIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      DEVIATIONS FROM IMMUNIZATION SCHEDULES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SPECIAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Antimalarial prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      VACCINE FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      FUTURE RESEARCH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29251206\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8303\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8303|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/0/33804\" title=\"table 1\">",
"      Available rabies biologics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/43/28347\" title=\"table 2\">",
"      Rabies postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/38/20075\" title=\"table 3\">",
"      Rabies preexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/6/16492\" title=\"table 4\">",
"      Rabies preexposure guide",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29624?source=related_link\">",
"      Clinical manifestations and diagnosis of rabies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/23/2418?source=related_link\">",
"      Patient information: Rabies (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=related_link\">",
"      Soft tissue infections due to dog and cat bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20088?source=related_link\">",
"      When to use rabies prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_21_2394="Immunizations for travel";
var content_f2_21_2394=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Immunizations for travel",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/21/2394/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/21/2394/contributors\">",
"     David Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/21/2394/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/21/2394/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/21/2394/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/21/2394/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/21/2394/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/21/2394/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H25118930\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;International travelers are frequently at risk of exposure to infectious pathogens and should seek advice about immunizations and other necessary prophylaxis prior to departure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In preparation for a trip, individuals should arrange a pre-travel consultation with either a specialized travel clinic or a primary care practice with expertise in travel medicine [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/3\">",
"     3",
"    </a>",
"    ]. The traveler should come to the visits with a record of prior immunizations and an itinerary.",
"   </p>",
"   <p>",
"    Immunization needs are based on the traveler's prior immunizations, health conditions, and likely exposures while traveling (",
"    <a class=\"graphic graphic_table graphicRef82688 \" href=\"UTD.htm?16/37/16990\">",
"     table 1",
"    </a>",
"    ). Those exposures depend upon the countries and regions to be visited and on the nature of potential exposures to infectious agents. For example, travelers with short-term tourism itineraries may have different requirements from those with longer-term occupational exposures. A pre-travel consultation enables updating of routine immunizations to protect against illness due to infections for which there is an increased risk of exposure during travel (such as diphtheria, measles, and varicella) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Information on the indications, dosing, side effects, timing, and contraindications for immunizations in travelers are provided by the Centers for Disease Control and Prevention (CDC) in an annual publication, Health Information for International Travel [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/6\">",
"     6",
"    </a>",
"    ] and online [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/7\">",
"     7",
"    </a>",
"    ]. The World Health Organization (WHO) also has online information [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/8\">",
"     8",
"    </a>",
"    ]. Information may be found at these sites:",
"    <a class=\"external\" href=\"file://wwwnc.cdc.gov/travel/content/diseases.aspx\">",
"     file://wwwnc.cdc.gov/travel/content/diseases.aspx",
"    </a>",
"    and",
"    <a class=\"external\" href=\"file://www.who.int/ith\">",
"     www.who.int/ith",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Issues related to immunizations for travelers are reviewed here. Other travel-related medical issues and measures to prevent malaria are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/48/8967?source=see_link\">",
"     \"Travel advice\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13370?source=see_link\">",
"     \"Prevention of malaria infection in travelers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TRAVEL IMMUNIZATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A standard immunization form should be part of the patient's medical record. Details to be recorded include vaccine type, dose, date of administration, manufacturer, lot number and site of administration [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/1\">",
"     1",
"    </a>",
"    ]. It is also important to document if a patient declines to receive any recommended vaccine.",
"   </p>",
"   <p>",
"    Available travel immunizations in the United States include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/13/14550?source=see_link\">",
"     yellow fever vaccine",
"    </a>",
"    , meningococcal vaccine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/7/25718?source=see_link\">",
"     typhoid vaccine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/30/44518?source=see_link\">",
"     hepatitis A vaccine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"     rabies vaccine",
"    </a>",
"    , and Japanese encephalitis vaccine. The indications, contraindications, precautions, dosing, and administration of these vaccines are discussed in the following sections.",
"   </p>",
"   <p>",
"    Minimum intervals between doses of vaccines are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef68034 \" href=\"UTD.htm?11/50/12064\">",
"     table 2",
"    </a>",
"    ). Dose and route of administration for selected vaccines are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef53960 \" href=\"UTD.htm?16/29/16861\">",
"     table 3",
"    </a>",
"    ). Contraindications and precautions for selected vaccines are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef70887 \" href=\"UTD.htm?11/59/12223\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Yellow fever vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Yellow fever (YF) is a mosquito-borne viral infection endemic in equatorial Africa and in areas of South America, but not in Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/6,9\">",
"     6,9",
"    </a>",
"    ]. Fatalities due to yellow fever acquired by unvaccinated tourists have occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. YF vaccination is legally required for entrance into specific countries, usually if the traveler is arriving from an infected country. However, many countries without a legal requirement have yellow fever transmission, so the traveler needs vaccination for their own protection.",
"   </p>",
"   <p>",
"    The YF vaccine is a live virus vaccine grown in chick embryos. Following vaccine administration, a low-level viremia with the vaccine virus often develops within three to seven days and persists for one to three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/21/15705?source=see_link&amp;anchor=H21#H21\">",
"     \"Yellow fever\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The vaccination certificate for YF is valid beginning 10 days after administration of YF vaccine for primary vaccine recipients; this corresponds to the time at which the majority of vaccine recipients demonstrate immunity. The YF vaccination certificate for international travel is valid for 10 years. In 2007, an updated International Certificate of Vaccination or Prophylaxis (ICVP) replaced the old certificates in response to the revision of the International Health Regulations in 2005; the ICVP is required for any yellow fever vaccination administered since December 15, 2007. Individuals vaccinated before that date may use the old certificate until it expires 10 years from the date of vaccination. The new certificates are available to health care providers through the US Government Printing Office [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/21/15705?source=see_link&amp;anchor=H28#H28\">",
"     \"Yellow fever\", section on 'Certificates'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3179721\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Travelers aged &ge;9 months who are traveling to or living in areas at risk for YF transmission in South America and Africa should be vaccinated. In addition, the International Health Regulations allow countries to require proof of YF vaccination as a condition of entry for travelers arriving from certain countries, to prevent importation and indigenous transmission of YF virus. Disease distribution maps and vaccine recommendations can be found at",
"    <a class=\"external\" href=\"file://www.who.int/ith\">",
"     www.who.int/ith",
"    </a>",
"    and at",
"    <a class=\"external\" href=\"file://wwwnc.cdc.gov/travel/content/diseases.aspx\">",
"     file://wwwnc.cdc.gov/travel/content/diseases.aspx",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651417\">",
"    <span class=\"h3\">",
"     Contraindications and precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the YF is a live attenuated vaccine, it should not be given to individuals with",
"    <strong>",
"    </strong>",
"    primary immunodeficiencies, transplant recipients, patients on immunosuppressive and immunomodulatory therapies, or patients with HIV whose CD4 count is",
"    <span class=\"nowrap\">",
"     &lt;200/mL.",
"    </span>",
"    Other contraindications include age &lt;6 months, allergy to a vaccine component, and thymic disorders. Precaution should be taken in infants aged 6 to 8 months and in individuals &ge;60 years of age. For travelers &gt;60 years, the risk of severe illness and death due to yellow fever infection should be balanced against the risk of serious vaccine effects (",
"    <a class=\"graphic graphic_table graphicRef70887 \" href=\"UTD.htm?11/59/12223\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pregnancy is a precaution for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/13/14550?source=see_link\">",
"     yellow fever vaccine",
"    </a>",
"    administration (in contrast to most other live vaccines which are contraindicated in pregnancy). If travel is unavoidable, and the risks for yellow fever virus exposure are felt to outweigh the vaccination risks, a pregnant woman should be vaccinated. If the risks for vaccination are felt to outweigh the risks for yellow fever virus exposure, pregnant women should be issued a medical waiver to fulfill health regulations [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some circumstances, patients require proof of YF vaccination for travel but YF vaccine administration is contraindicated. Official CDC and WHO resources distinguish between countries with International Health Regulation",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/13/14550?source=see_link\">",
"     yellow fever vaccine",
"    </a>",
"    entry requirements, and countries where vaccination is recommended because of potential exposure in an area with yellow fever transmission. For circumstances in which YF vaccine documentation must be presented to international customs officials according to International Health Regulations, the traveler can be provided with a Medical Letter of Waiver. For individuals planning travel to an area for which YF vaccine is recommended to avoid risk of infection in the unvaccinated traveler, serious consideration to a change in itinerary should be advised.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3179735\">",
"    <span class=\"h4\">",
"     Major adverse events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three well-characterized serious adverse events occur following YF vaccine administration (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/21/15705?source=see_link&amp;anchor=H23#H23\">",
"     \"Yellow fever\", section on 'Adverse effects'",
"    </a>",
"    .):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate hypersensitivity or anaphylactic reactions: These are uncommon and principally occur among persons with histories of allergies to egg or other substances [",
"      <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/17\">",
"       17",
"      </a>",
"      ]. The YF vaccine package insert contains a desensitization regimen which can be considered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=see_link\">",
"       \"Allergic reactions to vaccines\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      YF vaccine-associated neurologic disease (YEL-AND): YEL-AND is a serious but rarely fatal adverse event. YEL-AND manifests as several distinct clinical syndromes, including meningoencephalitis, Guillain-Barr&eacute; syndrome (GBS), acute disseminated encephalomyelitis (ADEM), and bulbar palsy. Meningoencephalitis occurs due to direct viral invasion of the central nervous system; the other syndromes are autoimmune manifestations [",
"      <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/9\">",
"       9",
"      </a>",
"      ]. The incidence rate of YF vaccine-associated encephalitis in very young infants has been estimated to be 50 to 400 cases per 100,000 population, and the overall reporting rate for YEL-AND is 0.4 to 0.8 cases per 100,000 doses distributed (rate in 60 to 69 year olds: 1.6 cases per 100,000 doses distributed and rate if &ge;70 years: 1.1 to 2.3 cases per 100,000 doses distributed) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/9\">",
"       9",
"      </a>",
"      ]. These estimates most likely are low given underreporting.",
"     </li>",
"     <li>",
"      YF vaccine-associated viscerotropic disease (YEL-AVD): YEL-AVD mimics naturally acquired YF disease, with proliferation and dissemination of the vaccine virus throughout the host tissues. This syndrome was first reported in 2001, and a total of about 57 cases has been described. The median time from vaccination to symptom onset is three days (range: one to eight days); death has occurred in 65 percent of cases. All known cases of YEL-AVD have occurred following a recipient&rsquo;s first YF vaccination, with no reported cases following booster doses. The reporting rate of YEL-AVD is 0.3 to 0.4 cases per 100,000 doses distributed, but higher rates have been reported in older individuals (1.0 to 1.1 cases per 100,000 doses distributed in persons aged 60 to 69 years and 2.3 to 3.2 cases per 100,000 doses distributed for persons aged &ge;70 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/9\">",
"       9",
"      </a>",
"      ]. In addition to older age, history of thymus disease or thymectomy are specific risk factors. All primary vaccinees should clearly be told to call with any symptoms of any kind within one week of vaccination and anyone with significant flu-like or febrile illnesses should be brought in for assessment as well as CBC and biochemistry.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651524\">",
"    <span class=\"h3\">",
"     Dosing and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dosing consists of a single 0.5 mL subcutaneous injection; boosting is required after 10 years (",
"    <a class=\"graphic graphic_table graphicRef53960 \" href=\"UTD.htm?16/29/16861\">",
"     table 3",
"    </a>",
"    ). YF vaccine should be administered either simultaneously or 30 days apart from other live viral vaccines. Other inactivated vaccines can be administered either simultaneously or at any time before or after YF vaccination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651582\">",
"    <span class=\"h2\">",
"     Meningococcal vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningococcal meningitis is a devastating bacterial infection transmitted by respiratory secretions with high mortality; large-scale epidemics mostly of type A occur in the so-called &ldquo;meningitis belt&rdquo; of Africa.",
"   </p>",
"   <p>",
"    There are two types of meningococcal vaccine, the quadrivalent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38965?source=see_link\">",
"     meningococcal polysaccharide vaccine",
"    </a>",
"    <span class=\"nowrap\">",
"     (MPSV4/Menomune),",
"    </span>",
"    which has been available since the 1980s, and the newer quadrivalent meningococcal conjugate vaccines",
"    <span class=\"nowrap\">",
"     (MCV4/Menactra",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     MenACWY/Menveo).",
"    </span>",
"    The conjugate vaccines are preferred over the polysaccharide vaccine. Both vaccines are licensed in the US for individuals between 2 and 55 years of age. For travelers, booster doses after the polysaccharide and the conjugate vaccine should be given every five years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link\">",
"     \"Meningococcal vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651707\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemics of meningococcal disease are frequent in the area of sub-Saharan Africa extending from Guinea in the west to Ethiopia in the east [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/8\">",
"     8",
"    </a>",
"    ]. A list of countries is available at:",
"    <a class=\"external\" href=\"file://wwwnc.cdc.gov/travel/content/diseases.aspx\">",
"     file://wwwnc.cdc.gov/travel/content/diseases.aspx",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27432?source=see_link\">",
"     \"Epidemiology of Neisseria meningitidis infection\"",
"    </a>",
"    .) Meningococcal vaccine is also recommended for travelers to this meningitis belt in Africa, especially during the dry season from December through June. Travelers to Saudi Arabia during the Hajj are required to have a certificate of vaccination with quadrivalent (A,C,Y,W-135) meningococcal vaccine before entering, issued not more than three years and not less than 10 days before arrival.",
"   </p>",
"   <p>",
"    Other (non-traveler) groups for whom meningococcus vaccine is warranted are outlined separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link&amp;anchor=H18#H18\">",
"     \"Meningococcal vaccines\", section on 'Country-specific vaccination guidelines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1652254\">",
"    <span class=\"h3\">",
"     Contraindications and precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity to other meningococcal-containing vaccines is a contraindication to vaccination. Immunization is safe in immunocompromised hosts and is specifically indicated for patients with deficiencies of terminal complement components or functional or anatomic asplenia (",
"    <a class=\"graphic graphic_table graphicRef70887 \" href=\"UTD.htm?11/59/12223\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link&amp;anchor=H15#H15\">",
"     \"Medical management of immune deficiency\", section on 'Vaccination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link&amp;anchor=H8#H8\">",
"     \"Prevention of sepsis in the asplenic patient\", section on 'Meningococcal vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An advisory has been issued regarding the occurrence of Guillain-Barr&eacute; syndrome (GBS) in recipients of MCV4 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Given the case-fatality rate for meningococcal disease of 10 to 14 percent and the significant morbidity in survivors, no changes to the recommendations for use of MCV4 have been issued [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38965?source=see_link\">",
"     \"Meningococcal polysaccharide vaccine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/35/10807?source=see_link\">",
"     \"Quadrivalent (A, C, Y, W-135) meningococcal conjugate vaccine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651721\">",
"    <span class=\"h3\">",
"     Dosing and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The schedules for the primary series and for revaccination are presented in the Table (",
"    <a class=\"graphic graphic_table graphicRef71265 \" href=\"UTD.htm?9/48/9999\">",
"     table 5",
"    </a>",
"    ). Conjugate vaccines are administered intramuscularly; polysaccharide vaccines are administered via subcutaneous injection (",
"    <a class=\"graphic graphic_table graphicRef53960 \" href=\"UTD.htm?16/29/16861\">",
"     table 3",
"    </a>",
"    ). Revaccination with MCV4 is indicated in patients previously vaccinated with MPSV4 or MCV4 who remain at increased risk for infection. If previously vaccinated at ages 2 to six years, revaccinate three years after the last dose. If previously vaccinated at &ge;7 years of age, revaccinate five years after the last dose. Persons who remain at high risk should then be revaccinated every five years (",
"    <a class=\"graphic graphic_table graphicRef71265 \" href=\"UTD.htm?9/48/9999\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link\">",
"     \"Meningococcal vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Typhoid vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typhoid fever is a systemic bacterial illness with fecal-oral transmission characterized by fever and abdominal symptoms. Salmonella enterica typhi infection is prevalent in many areas of Asia, Africa, and Latin America, and multidrug resistant strains of S. typhi are increasingly prevalent globally. There are two vaccines available for protection against S. typhi: live oral S. Typhi vaccine strain TY21a and parenteral Vi polysaccharide vaccine. Neither is completely effective against S. typhi and neither provides protection against paratyphoid fever. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/58/18345?source=see_link\">",
"     \"Treatment and prevention of typhoid fever\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/7/25718?source=see_link\">",
"     \"Typhoid vaccine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3179956\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typhoid vaccination is recommended for travelers to areas with a prolonged risk of exposure to S. typhi. The risk of acquiring typhoid fever increases with the duration of stay, although travelers have become ill during visits of less than one week to regions where the disease is endemic. Travelers visiting friends and relatives seem to be at particularly high risk of infection. A list of countries is available at:",
"    <a class=\"external\" href=\"file://wwwnc.cdc.gov/travel/content/diseases.aspx\">",
"     file://wwwnc.cdc.gov/travel/content/diseases.aspx",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1652556\">",
"    <span class=\"h3\">",
"     Contraindications and precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oral S. Typhi vaccine a live attenuated vaccine so should not be administered to individuals with immunodeficiency, acute febrile illness or acute gastrointestinal illness (",
"    <a class=\"graphic graphic_table graphicRef70887 \" href=\"UTD.htm?11/59/12223\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/7/25718?source=see_link\">",
"     \"Typhoid vaccine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3179963\">",
"    <span class=\"h3\">",
"     Dosing and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The parenteral polysaccharide Vi vaccine is administered as a single 0.5 mL intramuscular injection. A booster dose is required two to three years later (",
"    <a class=\"graphic graphic_table graphicRef53960 \" href=\"UTD.htm?16/29/16861\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/7/25718?source=see_link\">",
"     typhoid vaccine",
"    </a>",
"    is administered as a four dose course (days 1, 3, 5 and 7), and is supplied as a packet of enteric-coated capsules that must be kept refrigerated (",
"    <a class=\"graphic graphic_table graphicRef53960 \" href=\"UTD.htm?16/29/16861\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/21\">",
"     21",
"    </a>",
"    ]. The primary course needs to be repeated five years after initial administration. It is acceptable to administer other live vaccines concurrently with the oral typhoid vaccine.",
"   </p>",
"   <p>",
"    The oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/7/25718?source=see_link\">",
"     typhoid vaccine",
"    </a>",
"    should not be administered within 72 hours of antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/22\">",
"     22",
"    </a>",
"    ]. The antimalarial drug proguanil (available in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    as Malarone) has been shown to decrease the immune response to oral typhoid vaccine; therefore it may be administered only if 10 or more days have elapsed since the final dose of oral typhoid vaccine was administered. The antimalarial drugs",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    have not been shown to decrease the immune response to oral typhoid vaccine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hepatitis A vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis A is a viral infection transmitted via the fecal-oral route that can lead to hepatic failure in rare cases. In surveillance data collected from 1988-2004, the incidence of hepatitis A for travelers to countries of high or intermediate risk was 3 to 11 per 100,000 person-months abroad, and the incidence for travelers presumed to be nonimmune was 6 to 28 per 100,000 for travelers [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7591?source=see_link\">",
"     \"Overview of hepatitis A virus infection in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/38/1641?source=see_link\">",
"     \"Hepatitis A virus vaccination and postexposure prophylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16456867\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccination is warranted for travelers to countries with intermediate to high endemicity of HAV. A list of countries is available at:",
"    <a class=\"external\" href=\"file://wwwnc.cdc.gov/travel/content/diseases.aspx\">",
"     file://wwwnc.cdc.gov/travel/content/diseases.aspx",
"    </a>",
"    . The list includes all developing countries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3180199\">",
"    <span class=\"h3\">",
"     Contraindications and precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/30/44518?source=see_link\">",
"     hepatitis A vaccine",
"    </a>",
"    or any component of the formulation is a contraindication to vaccination (",
"    <a class=\"graphic graphic_table graphicRef70887 \" href=\"UTD.htm?11/59/12223\">",
"     table 4",
"    </a>",
"    ). The hepatitis A vaccines are acceptable for use in pregnancy and for immunocompromised individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/30/44518?source=see_link\">",
"     \"Hepatitis A vaccine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16456785\">",
"    <span class=\"h3\">",
"     Dosing and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/30/44518?source=see_link\">",
"     hepatitis A vaccine",
"    </a>",
"    include monovalent vaccines HAVRIX or VAQTA. Available combination vaccine formulations include Twinrix (includes hepatitis B) and Vivaxim (includes typhoid Vi; not available in the United States).",
"   </p>",
"   <p>",
"    One dose of single antigen",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/30/44518?source=see_link\">",
"     hepatitis A vaccine",
"    </a>",
"    administered at any time prior to departure provides adequate initial protection for healthy individuals &le;40 years (",
"    <a class=\"graphic graphic_table graphicRef67893 \" href=\"UTD.htm?38/43/39611\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/26\">",
"     26",
"    </a>",
"    ]. A second dose of vaccine 6 to 12 months after the initial dose is recommended and provides longer term protection (",
"    <a class=\"graphic graphic_table graphicRef53960 \" href=\"UTD.htm?16/29/16861\">",
"     table 3",
"    </a>",
"    ). If the immunization schedule is interrupted, the second dose can be given without restarting the series. No additional booster doses are recommended, as data suggest that long-term protection is achieved. A vaccination series started with one brand of vaccine may be completed with the same or other brand of hepatitis A vaccine.",
"   </p>",
"   <p>",
"    Older adults, immunocompromised patients, and individuals with chronic liver disease planning to depart for an area endemic for hepatitis A within &le;2 weeks should receive the initial dose of the vaccine as well as immunoglobulin (IG; 0.02",
"    <span class=\"nowrap\">",
"     mL/kg)",
"    </span>",
"    at a separate anatomic injection site. If IG is unavailable or patients elect not to receive it,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/30/44518?source=see_link\">",
"     hepatitis A vaccine",
"    </a>",
"    alone should still be given. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/38/1641?source=see_link\">",
"     \"Hepatitis A virus vaccination and postexposure prophylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Travelers who choose not to receive the vaccination, are aged &lt;12 months, or are allergic to a vaccine component should receive a single dose of IG. IG provides protection for about 3 months; administration must be repeated if the travel period is &gt;5 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hepatitis B vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis B is a viral infection transmitted by bodily fluid exposure that can lead to hepatic failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hepatocellular carcinoma. It is estimated that there are more than 350 million HBV carriers in the world, of whom roughly one million die annually from HBV-related liver disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=see_link\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3180254\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccination is warranted for travelers to countries with intermediate to high endemicity of HBV (ie, with hepatitis B surface antigen [HBsAg] prevalence &ge;2 percent); a list of countries is available at:",
"    <a class=\"external\" href=\"file://wwwnc.cdc.gov/travel/content/diseases.aspx\">",
"     file://wwwnc.cdc.gov/travel/content/diseases.aspx",
"    </a>",
"    . Risk groups include health care workers, adventure travelers, Peace Corps volunteers, missionaries, military personnel, and medical tourists [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/6\">",
"     6",
"    </a>",
"    ]. Hepatitis B immunization should also be considered for any traveler with potential contact with blood or bodily secretions, potential sexual contact, or potential need for medical or dental procedures while traveling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16456933\">",
"    <span class=\"h3\">",
"     Contraindications and precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    or any component of the formulation is a contraindication to vaccination (",
"    <a class=\"graphic graphic_table graphicRef70887 \" href=\"UTD.htm?11/59/12223\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     \"Hepatitis B vaccine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     Hepatitis B vaccine",
"    </a>",
"    can be administered to immunosuppressed patients, although vaccine immunogenicity is lower in these groups [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/27\">",
"     27",
"    </a>",
"    ]. For individuals with underlying comorbidities that may interfere with seroconversion, antibody titers can be checked to ensure adequate vaccine response has occurred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3180261\">",
"    <span class=\"h3\">",
"     Dosing and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two formulations of recombinant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    available in the United States (Recombivax HB and Engerix-B). There is also a combination formulation that includes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/30/44518?source=see_link\">",
"     hepatitis A vaccine",
"    </a>",
"    (Twinrix).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     Hepatitis B vaccine",
"    </a>",
"    is administered in three intramuscular doses: the initial dose is followed by repeat doses at one and six months after the first dose (",
"    <a class=\"graphic graphic_table graphicRef53960 \" href=\"UTD.htm?16/29/16861\">",
"     table 3",
"    </a>",
"    ). Immunization should begin six months prior to travel. If this schedule is not feasible, some protection is afforded by one or two doses administered before travel. An accelerated regimen (with doses given on days 0, 7, and 21) can be administered to travelers who cannot complete the full series prior to departure. Travelers who receive the accelerated regimen should receive a booster at least six months later to optimize long-term immunity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The bivalent vaccine can be used to complete immunizations series started with monovalent hepatitis A and B vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1652399\">",
"    <span class=\"h2\">",
"     Rabies vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rabies is a viral disease transmitted by dogs, bats, and other animals that leads to encephalopathy and death. Rabies is endemic in most countries of Asia, Africa, and Central and South America [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16457167\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rabies pre-exposure vaccination is indicated for travelers visiting areas where rabies is endemic who anticipate contact with animals and limited access to immediate medical care [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/28\">",
"     28",
"    </a>",
"    ]. Children are at increased risk as they are more likely than adults to play with animals, and they may not reliably report exposures not associated with significant injury. A list of countries is available at:",
"    <a class=\"external\" href=\"file://wwwnc.cdc.gov/travel/content/diseases.aspx\">",
"     file://wwwnc.cdc.gov/travel/content/diseases.aspx",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16457144\">",
"    <span class=\"h3\">",
"     Contraindications and precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"     rabies vaccine",
"    </a>",
"    or any component of the formulation is a contraindication to vaccination (",
"    <a class=\"graphic graphic_table graphicRef70887 \" href=\"UTD.htm?11/59/12223\">",
"     table 4",
"    </a>",
"    ). The rabies vaccines are acceptable for use in pregnancy and for immunocompromised individuals. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"     \"Rabies virus vaccine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1652413\">",
"    <span class=\"h3\">",
"     Dosing and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"     rabies vaccine",
"    </a>",
"    available in the United States: human diploid cell vaccine (HDCV) and purified chick embryo cell vaccine (PCECV). Additional vaccines are available outside the United States; they are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2393?source=see_link&amp;anchor=H11#H11\">",
"     \"Rabies immune globulin and vaccine\", section on 'Outside the US'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the United States, preexposure vaccination consists of a series of three 1 mL intramuscular doses on days 0, 7, and 21 or 28 (",
"    <a class=\"graphic graphic_table graphicRef53960 \" href=\"UTD.htm?16/29/16861\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/6\">",
"     6",
"    </a>",
"    ]. Rabies vaccination outside the United States, including intradermal vaccination, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2393?source=see_link&amp;anchor=H11#H11\">",
"     \"Rabies immune globulin and vaccine\", section on 'Outside the US'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For typical travelers, no further booster doses are ever required in order to maintain an &ldquo;immunized&rdquo; status. Only rare individuals at high ongoing risk, such as veterinarians or wildlife workers, should have antibody levels checked regularly and a booster given when antibody titers fall below 0.5",
"    <span class=\"nowrap\">",
"     IU/mL.",
"    </span>",
"    Preexposure immunization does not eliminate the need for postexposure treatment with two booster doses spaced by three days.",
"   </p>",
"   <p>",
"    The approach to rabies postexposure prophylaxis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20088?source=see_link\">",
"     \"When to use rabies prophylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3180656\">",
"    <span class=\"h2\">",
"     Japanese encephalitis vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Japanese encephalitis (JE) is an arboviral encephalitis endemic throughout most of Asia and parts of the western Pacific. The highest risk of JE exposure occurs in rural agricultural areas, often associated with rice production and flooding irrigation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5208?source=see_link\">",
"     \"Japanese encephalitis: Epidemiology, diagnosis, treatment and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are two JEV vaccines that have been licensed in the United States: an inactivated Vero cell-derived vaccine (JE-VC; IXIARO) and an inactivated mouse brain-derived vaccine (JE-MB; JE-VAX). Production of JE-MB has been discontinued. JE-VC is licensed for use in individuals &ge;17 years of age.",
"   </p>",
"   <p>",
"    Outside the United States, a live attenuated yellow fever-JE chimeric viral vaccine (IMOJEV) has been licensed in Australia as a single 0.5 mL subcutaneous dose for individuals over 12 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/29\">",
"     29",
"    </a>",
"    ]. Since it is a live attenuated vaccine, it should not be used in immunocompromised individuals and its safety in pregnancy has not been evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3180702\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;JE vaccination is appropriate for travelers visiting endemic areas during periods of JE transmission. Indications are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef54113 \" href=\"UTD.htm?14/33/14876\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/30\">",
"     30",
"    </a>",
"    ]. A list of countries can be found at:",
"    <a class=\"external\" href=\"file://wwwnc.cdc.gov/travel/content/diseases.aspx\">",
"     file://wwwnc.cdc.gov/travel/content/diseases.aspx",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98992777\">",
"    <span class=\"h3\">",
"     Contraindications and precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/38/40549?source=see_link\">",
"     Japanese encephalitis virus vaccine",
"    </a>",
"    , thimerosal (for JE-VAX), or any component of the formulation is a contraindication to vaccination (",
"    <a class=\"graphic graphic_table graphicRef70887 \" href=\"UTD.htm?11/59/12223\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3180716\">",
"    <span class=\"h3\">",
"     Dosing and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary immunization schedule for JE-VC is two doses administered intramuscularly on days 0 and 28. The dose is 0.5 mL for persons &ge;17 years of age, and the two-dose series should be completed at least one week prior to travel (",
"    <a class=\"graphic graphic_table graphicRef53960 \" href=\"UTD.htm?16/29/16861\">",
"     table 3",
"    </a>",
"    ). The vaccine is not licensed for use in children or pregnant women. A booster dose should be administered at one year for those with ongoing risk [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3180683\">",
"    <span class=\"h2\">",
"     Cholera vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholera is a diarrheal illness caused by infection with the gram-negative bacterium Vibrio cholerae; it is characterized by severe, watery diarrhea, which can rapidly lead to dehydration. Epidemics of cholera have occurred around the world, although infection among travelers is not common [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Routine immunization is not recommended for conventional travelers from the US [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/6\">",
"     6",
"    </a>",
"    ], although vaccination is appropriate for aid and refugee workers to endemic areas in high risk situations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of Vibrio cholerae infection\", section on 'Vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No cholera vaccine is currently licensed in the United States. Dukoral, a killed whole-cell oral vaccine with the nontoxic B subunit of cholera toxin, is licensed against cholera in many other countries. This vaccine also provides limited (&lt;50 percent) protection against infection with enterotoxigenic Escherichia coli. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29145?source=see_link&amp;anchor=H30#H30\">",
"     \"Travelers' diarrhea\", section on 'Vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3180858\">",
"    <span class=\"h2\">",
"     Tick-borne encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tick-borne encephalitis is a viral infection of the central nervous system that is transmitted by ticks. The disease occurs in Scandinavia, countries of the former Soviet Union, and in western and central Europe and occasionally as far south as Greece or the former Yugoslavia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/34\">",
"     34",
"    </a>",
"    ]. The disease is primarily transmitted from April through August, when the tick vector is most active. Infection may also occur through the ingestion of raw milk or cheese from cows, sheep, or goats. Effective vaccines are available in Europe and Canada; vaccines are not available in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38760?source=see_link&amp;anchor=H16#H16\">",
"     \"Arthropod-borne encephalitides\", section on 'Tick-borne encephalitis virus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3180901\">",
"    <span class=\"h1\">",
"     ROUTINE IMMUNIZATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pre-travel visit provides an opportunity to ensure that routine immunizations (including influenza, Tdap, MMR, poliovirus, and varicella vaccinations) are current, as discussed in the following sections.",
"   </p>",
"   <p>",
"    Minimum intervals between doses of vaccines are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef68034 \" href=\"UTD.htm?11/50/12064\">",
"     table 2",
"    </a>",
"    ). Guidelines for spacing of live and inactivated agents are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef59103 \" href=\"UTD.htm?23/6/23659\">",
"     table 8",
"    </a>",
"    ). Information related to dosing and administration for selected vaccines is summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef53960 \" href=\"UTD.htm?16/29/16861\">",
"     table 3",
"    </a>",
"    ). Contraindications and precautions for selected vaccines are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef70887 \" href=\"UTD.htm?11/59/12223\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Influenza vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza is a viral illness transmitted by respiratory secretions; it is a common vaccine-preventable infection in travelers [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/6,35,36\">",
"     6,35,36",
"    </a>",
"    ]. In the tropics, influenza occurs throughout the year [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/35\">",
"     35",
"    </a>",
"    ]. In the northern and southern hemispheres, influenza occurs during the winter months (December through February or April to September, respectively), although summertime outbreaks have occurred on cruise ships [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/37-41\">",
"     37-41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=see_link\">",
"     \"Epidemiology of influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Influenza vaccination is appropriate for all travelers to destinations where influenza is being transmitted at that time. Those for whom it is especially important include individuals over 50 years of age traveling to the tropics or to the northern or southern hemisphere during winter months, and those traveling on cruise ships or in large groups [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/6,42\">",
"     6,42",
"    </a>",
"    ]. Contraindications, precautions, dosing, and administration are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link&amp;anchor=H13#H13\">",
"     \"Seasonal influenza vaccination in children\", section on 'Travelers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3181211\">",
"    <span class=\"h2\">",
"     Tetanus, diphtheria and pertussis vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;All travelers are at risk for pertussis, a communicable respiratory disease due to infection with Bordetella pertussis. All adults aged 19 to 64 years should receive a single dose of Tdap, even if Td booster has been administered recently. Tdap vaccination is also recommended by the ACIP for adults &ge;65 who have close contact with infants aged younger than one year (such as grandparents, child care providers and health care providers). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=see_link&amp;anchor=H12882667#H12882667\">",
"     \"Treatment and prevention of Bordetella pertussis infection in adolescents and adults\", section on 'Vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tetanus is a nervous system disorder characterized by muscle spasms caused by the toxin producing anaerobe Clostridium tetani; infection typically occurs following traumatic injury. All travelers should have current tetanus immunization (eg, within the last 10 years prior to travel). All adults should receive a single dose of Tdap as a tetanus booster (in place of the tetanus and diphtheria toxoid vaccine). Thereafter, subsequent tetanus boosters should be administered every 10 years with Td (not Tdap). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3181096\">",
"    <span class=\"h2\">",
"     Measles, mumps and rubella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Travelers are at risk for measles and mumps infection. Measles is a highly contagious viral illness spread by respiratory droplets; complications include pneumonia, otitis media, and encephalitis. Several cases of measles acquired from infected patients on aircraft returning from international destinations have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Mumps is a contagious viral illness that leads to painful swelling of the salivary glands; complications include orchitis and central nervous system involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42246?source=see_link\">",
"     \"Epidemiology and transmission of measles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8154?source=see_link\">",
"     \"Epidemiology, clinical manifestations, diagnosis and management of mumps\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children traveling outside the United States should receive MMR vaccination sooner than the standard immunization schedule. Prior to departure children 12 months of age or older should have received two doses of MMR (measles, mumps, and rubella) vaccine separated by at least 28 days, with the first dose administered on or after the first birthday. Children aged 6 to 11 months should receive one dose of MMR before departure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link&amp;anchor=H22#H22\">",
"     \"Standard immunizations for children and adolescents\", section on 'MMR vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MMR vaccination for adults is indicated for individuals born in 1957 or later in the United States without a history of disease, or without a history of two doses of an adequate live vaccine at any time after age 12 months. Although individuals born before 1957 in the US are presumed to be immune (exceptions include US health care workers and women of childbearing age), two doses of MMR vaccine spaced by one month should be strongly considered for unvaccinated individuals without other evidence of immunity who were born before 1957 (in the US) and are traveling for purposes of health care or humanitarian work potentially entailing close contact with ill individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22793?source=see_link&amp;anchor=H14#H14\">",
"     \"Prevention and treatment of measles\", section on 'Measles vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MMR vaccination is contraindicated in pregnant and immunocompromised patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22793?source=see_link&amp;anchor=H23#H23\">",
"     \"Prevention and treatment of measles\", section on 'Pregnancy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/49/13081?source=see_link\">",
"     \"Travel advice for immunocompromised hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further details regarding measles vaccination are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22793?source=see_link\">",
"     \"Prevention and treatment of measles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7672819\">",
"    <span class=\"h2\">",
"     Poliovirus vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poliomyelitis is a viral infection transmitted via the fecal-oral route that can affect the central nervous system, leading to muscle weakness and flaccid paralysis. There are two types of polio vaccine: an oral polio vaccine (OPV) containing live attenuated polioviruses, and an inactivated polio vaccine (IPV). In the United States and many regions of the world, only IPV is available, given the rare risk of vaccine-associated paralytic poliomyelitis (VAPP) with OPV. &nbsp;",
"   </p>",
"   <p>",
"    Travelers to areas or countries where polio is endemic or epidemic should receive polio vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/45\">",
"     45",
"    </a>",
"    ]. As of 2012, endemic countries include Pakistan, Afghanistan, and Nigeria. The Centers for Disease Control maintains a",
"    <a class=\"external\" href=\"file://wwwnc.cdc.gov/travel/notices/in-the-news/polio-outbreaks.htm\">",
"     list of countries",
"    </a>",
"    for which travelers are recommended to receive polio boosters. Adults require a primary series of OPV or IPV and a single booster dose of IPV [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/46\">",
"     46",
"    </a>",
"    ]. Adults who are unvaccinated or whose vaccination status is not documented should receive a primary vaccination series with IPV (two doses of IPV at four to eight week intervals and a third dose 6 to 12 months after the second dose) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/46\">",
"     46",
"    </a>",
"    ]. If this regimen cannot be completed prior to travel, see the ACIP Polio Vaccine recommendations for detailed scheduling [",
"    <a class=\"abstract\" href=\"UTD.htm?2/21/2394/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17223?source=see_link\">",
"     \"Poliovirus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Travelers to Saudi Arabia during the Hajj are required to provide documentation of vaccination for infants and children up to 15 years of age. For current information on the status of polio eradication efforts and vaccine recommendations, see",
"    <a class=\"external\" href=\"file://wwwnc.cdc.gov/travel/content/in-the-news/polio-outbreaks.aspx\">",
"     file://wwwnc.cdc.gov/travel/content/in-the-news/polio-outbreaks.aspx",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3180941\">",
"    <span class=\"h2\">",
"     Varicella vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella is a contagious viral infection transmitted by respiratory droplets; complications include pneumonia and encephalitis. It is endemic in most countries.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     Varicella vaccine",
"    </a>",
"    is recommended for all non-immune adults and adolescents born after 1979 in the US and all non-immune persons born outside the US, regardless of travel plans. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     IMMUNOCOMPROMISED PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, severely immunocompromised patients should not receive live vaccines. Live vaccines include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/13/14550?source=see_link\">",
"     yellow fever vaccine",
"    </a>",
"    , oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/7/25718?source=see_link\">",
"     typhoid vaccine",
"    </a>",
"    , nasal influenza vaccine, OPV, MMR, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    . Inactivated vaccines include meningococcal vaccine, parenteral typhoid vaccine, hepatitis A and B vaccines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"     rabies vaccine",
"    </a>",
"    , Japanese encephalitis vaccine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    , IPV, Tdap, and Td.",
"   </p>",
"   <p>",
"    Issues related to travel immunizations in immunocompromised hosts are discussed in detail separately, as are issues related to immunizations in HIV-infected individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/49/13081?source=see_link\">",
"     \"Travel advice for immunocompromised hosts\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link\">",
"     \"Immunizations in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/44/21187?source=see_link\">",
"       \"Patient information: Vaccines for travel (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23619?source=see_link\">",
"       \"Patient information: Vaccines for adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=see_link\">",
"       \"Patient information: Vaccines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=see_link\">",
"       \"Patient information: General travel advice (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7673081\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      International travelers are frequently at risk of exposure to infectious pathogens and should seek advice about immunizations and other necessary prophylaxis prior to departure. The immunizations should be tailored to individual itinerary details. Disease distribution maps and vaccine recommendations from the Centers for Disease Control (CDC) and the World Health Organization (WHO) can be found at",
"      <a class=\"external\" href=\"file://wwwnc.cdc.gov/travel/content/diseases.aspx\">",
"       file://wwwnc.cdc.gov/travel/content/diseases.aspx",
"      </a>",
"      and",
"      <a class=\"external\" href=\"file://www.who.int/ith\">",
"       www.who.int/ith",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H25118930\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Available travel immunizations in the United States include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/13/14550?source=see_link\">",
"       yellow fever vaccine",
"      </a>",
"      , meningococcal vaccine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/7/25718?source=see_link\">",
"       typhoid vaccine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/30/44518?source=see_link\">",
"       hepatitis A vaccine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"       rabies vaccine",
"      </a>",
"      , and Japanese encephalitis vaccine. The indications, contraindications, precautions, dosing and administration of these vaccines are discussed above. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Travel immunizations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pre-travel visit provides an opportunity to ensure that routine immunizations (including influenza, Tdap, MMR, poliovirus, and varicella vaccinations) are current. Travelers to destinations in the developing world are at increased risk for infection due to these pathogens and in some cases additional doses are indicated. (See",
"      <a class=\"local\" href=\"#H3180901\">",
"       'Routine immunizations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Minimum intervals between doses of vaccines are summarized in the Table (",
"      <a class=\"graphic graphic_table graphicRef68034 \" href=\"UTD.htm?11/50/12064\">",
"       table 2",
"      </a>",
"      ). Guidelines for spacing of live and inactivated agents are summarized in the Table (",
"      <a class=\"graphic graphic_table graphicRef59103 \" href=\"UTD.htm?23/6/23659\">",
"       table 8",
"      </a>",
"      ). Information related to dosing and administration for selected vaccines is summarized in the Table (",
"      <a class=\"graphic graphic_table graphicRef53960 \" href=\"UTD.htm?16/29/16861\">",
"       table 3",
"      </a>",
"      ). Contraindications and precautions for selected vaccines are summarized in the Table (",
"      <a class=\"graphic graphic_table graphicRef70887 \" href=\"UTD.htm?11/59/12223\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In general, severely immunocompromised patients should not receive live vaccines. Live vaccines include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/13/14550?source=see_link\">",
"       yellow fever vaccine",
"      </a>",
"      , oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/7/25718?source=see_link\">",
"       typhoid vaccine",
"      </a>",
"      , nasal influenza vaccine, OPV, MMR and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      . Inactivated vaccines include meningococcal vaccine, parenteral typhoid vaccine, hepatitis A and B vaccines,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"       rabies vaccine",
"      </a>",
"      , Japanese encephalitis vaccine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=see_link\">",
"       inactivated influenza vaccine",
"      </a>",
"      , IPV, Tdap and Td. Issues related to travel immunizations in immunocompromised hosts are discussed in detail separately, as are issues related to immunizations in HIV-infected individuals. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/49/13081?source=see_link\">",
"       \"Travel advice for immunocompromised hosts\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link\">",
"       \"Immunizations in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/1\">",
"      Hill DR, Ericsson CD, Pearson RD, et al. The practice of travel medicine: guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/2\">",
"      Centers for Disease Control (U.S). Advice for travelers. Treat Guidel Med Lett 2009; 7:83.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.istm.org/ (Accessed on March 30, 2011).",
"    </li>",
"    <li>",
"     General recommendations on immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). 2011. file://www.cdc.gov/mmwr/PDF/rr/rr6002.pdf?source=govdelivery (Accessed on January 27, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/5\">",
"      National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     CDC. Health information for international travel 2011-2012. DHHS, Atlanta, GA 2011.",
"    </li>",
"    <li>",
"     www.cdc.gov/travel (Accessed on January 26, 2011).",
"    </li>",
"    <li>",
"     www.who.int/ith (Accessed on January 26, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/9\">",
"      Staples JE, Gershman M, Fischer M, Centers for Disease Control and Prevention (CDC). Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). Fatal yellow fever in a traveler returning from Venezuela, 1999. MMWR Morb Mortal Wkly Rep 2000; 49:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/11\">",
"      Centers for Disease Control and Prevention (CDC). Fatal yellow fever in a traveler returning from Amazonas, Brazil, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/12\">",
"      Colebunders R, Mariage JL, Coche JC, et al. A Belgian traveler who acquired yellow fever in the Gambia. Clin Infect Dis 2002; 35:e113.",
"     </a>",
"    </li>",
"    <li>",
"     US Government Printing Office (GPO) telephone (866-512-1800); online at file://bookstore.gpo.gov/collections/vaccination.jsp (Accessed March 13, 2008).",
"    </li>",
"    <li>",
"     World Health Organization. International Health Regulations file://www.who.int/ihr/en/.",
"    </li>",
"    <li>",
"     file://wwwnc.cdc.gov/travel/content/diseases.aspx (Accessed on January 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/16\">",
"      Marfin AA, Eidex RS, Kozarsky PE, Cetron MS. Yellow fever and Japanese encephalitis vaccines: indications and complications. Infect Dis Clin North Am 2005; 19:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/17\">",
"      Mosimann B, Stoll B, Francillon C, P&eacute;coud A. Yellow fever vaccine and egg allergy. J Allergy Clin Immunol 1995; 95:1064.",
"     </a>",
"    </li>",
"    <li>",
"     FDA News. FDA and CDC issue alert on Menactra meningococcal vaccine and Guillain Barre Syndrome. September 30, 2005. www.fda.gov/bbs/topics/NEWS/2005/NEW01238.html (Accessed on May 29, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/19\">",
"      Centers for Disease Control and Prevention (CDC). Guillain-Barr&eacute; syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June-July 2005. MMWR Morb Mortal Wkly Rep 2005; 54:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/20\">",
"      Bilukha OO, Rosenstein N, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/21\">",
"      Kaplan DT, Hill DR. Compliance with live, oral Ty21a typhoid vaccine. JAMA 1992; 267:1074.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.bernaproducts.com/v_faq/#6.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/23\">",
"      Mutsch M, Spicher VM, Gut C, Steffen R. Hepatitis A virus infections in travelers, 1988-2004. Clin Infect Dis 2006; 42:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/24\">",
"      Arslan M, Wiesner RH, Poterucha JJ, Zein NN. Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. Transplantation 2001; 72:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/25\">",
"      Wallace MR, Brandt CJ, Earhart KC, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis 2004; 39:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/26\">",
"      Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2007; 56:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/27\">",
"      Tayal SC, Sankar KN. Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV-infected individuals. AIDS 1994; 8:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/28\">",
"      Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention--United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2008; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.tga.gov.au/pmeds/auspar/auspar-imojev.pdf (Accessed on March 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/30\">",
"      Fischer M, Lindsey N, Staples JE, et al. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/31\">",
"      Mahon BE, Mintz ED, Greene KD, et al. Reported cholera in the United States, 1992-1994: a reflection of global changes in cholera epidemiology. JAMA 1996; 276:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/32\">",
"      Weber JT, Levine WC, Hopkins DP, Tauxe RV. Cholera in the United States, 1965-1991. Risks at home and abroad. Arch Intern Med 1994; 154:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/33\">",
"      Centers for Disease Control and Prevention (CDC). Update on cholera --- Haiti, Dominican Republic, and Florida, 2010. MMWR Morb Mortal Wkly Rep 2010; 59:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/34\">",
"      Tick-Borne Encephalitis Among U.S. Travelers to Europe and Asia --- 2000-2009. MMWR Morb Mortal Wkly Rep 2010; 59(11):335-338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/35\">",
"      Leder K, Sundararajan V, Weld L, et al. Respiratory tract infections in travelers: a review of the GeoSentinel surveillance network. Clin Infect Dis 2003; 36:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/36\">",
"      Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/37\">",
"      Uyeki TM, Zane SB, Bodnar UR, et al. Large summertime influenza A outbreak among tourists in Alaska and the Yukon Territory. Clin Infect Dis 2003; 36:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/38\">",
"      Miller JM, Tam TW, Maloney S, et al. Cruise ships: high-risk passengers and the global spread of new influenza viruses. Clin Infect Dis 2000; 31:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/39\">",
"      Ferson M, Paraskevopoulos P, Hatzi S, et al. Presumptive summer influenza A: an outbreak on a trans-Tasman cruise. Commun Dis Intell 2000; 24:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/40\">",
"      Centers for Disease Control and Prevention (CDC). Influenza B virus outbreak on a cruise ship--Northern Europe, 2000. MMWR Morb Mortal Wkly Rep 2001; 50:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/41\">",
"      Christenson B, Lidin-Janson G, Kallings I. Outbreak of respiratory illness on board a ship cruising to ports in southern Europe and northern Africa. J Infect 1987; 14:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/42\">",
"      Fiore AE, Shay DK, Broder K, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/43\">",
"      Vitek CR, Redd SC, Redd SB, Hadler SC. Trends in importation of measles to the United States, 1986-1994. JAMA 1997; 277:1952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/44\">",
"      Amornkul PN, Takahashi H, Bogard AK, et al. Low risk of measles transmission after exposure on an international airline flight. J Infect Dis 2004; 189 Suppl 1:S81.",
"     </a>",
"    </li>",
"    <li>",
"     www.polioeradication.org (Accessed on March 30, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/21/2394/abstract/46\">",
"      Prevots DR, Burr RK, Sutter RW, et al. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3890 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-77.94.48.4-BBE44F2A81-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_21_2394=[""].join("\n");
var outline_f2_21_2394=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7673081\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25118930\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TRAVEL IMMUNIZATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Yellow fever vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3179721\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1651417\">",
"      - Contraindications and precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3179735\">",
"      Major adverse events",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1651524\">",
"      - Dosing and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1651582\">",
"      Meningococcal vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1651707\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1652254\">",
"      - Contraindications and precautions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1651721\">",
"      - Dosing and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Typhoid vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3179956\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1652556\">",
"      - Contraindications and precautions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3179963\">",
"      - Dosing and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hepatitis A vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16456867\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3180199\">",
"      - Contraindications and precautions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16456785\">",
"      - Dosing and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hepatitis B vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3180254\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16456933\">",
"      - Contraindications and precautions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3180261\">",
"      - Dosing and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1652399\">",
"      Rabies vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16457167\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16457144\">",
"      - Contraindications and precautions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1652413\">",
"      - Dosing and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3180656\">",
"      Japanese encephalitis vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3180702\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H98992777\">",
"      - Contraindications and precautions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3180716\">",
"      - Dosing and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3180683\">",
"      Cholera vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3180858\">",
"      Tick-borne encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3180901\">",
"      ROUTINE IMMUNIZATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Influenza vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3181211\">",
"      Tetanus, diphtheria and pertussis vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3181096\">",
"      Measles, mumps and rubella",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7672819\">",
"      Poliovirus vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3180941\">",
"      Varicella vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      IMMUNOCOMPROMISED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7673081\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3890\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3890|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/37/16990\" title=\"table 1\">",
"      Immunization for travel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/50/12064\" title=\"table 2\">",
"      Minimum intervals between doses of recommended routine vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/29/16861\" title=\"table 3\">",
"      Dose and route of administration for selected vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/59/12223\" title=\"table 4\">",
"      Contraindications and precautions to vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/48/9999\" title=\"table 5\">",
"      Meningococcal vaccination indications in the US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/43/39611\" title=\"table 6\">",
"      Dose regimen HAV vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/33/14876\" title=\"table 7\">",
"      JE vaccine recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/6/23659\" title=\"table 8\">",
"      Guidelines for spacing live and inactivated antigens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=related_link\">",
"      Allergic reactions to vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38760?source=related_link\">",
"      Arthropod-borne encephalitides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42246?source=related_link\">",
"      Epidemiology and transmission of measles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27432?source=related_link\">",
"      Epidemiology of Neisseria meningitidis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=related_link\">",
"      Epidemiology of influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8154?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis and management of mumps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=related_link\">",
"      Epidemiology, transmission, and prevention of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/30/44518?source=related_link\">",
"      Hepatitis A vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/38/1641?source=related_link\">",
"      Hepatitis A virus vaccination and postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=related_link\">",
"      Hepatitis B vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5208?source=related_link\">",
"      Japanese encephalitis: Epidemiology, diagnosis, treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38965?source=related_link\">",
"      Meningococcal polysaccharide vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=related_link\">",
"      Overview of Vibrio cholerae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7591?source=related_link\">",
"      Overview of hepatitis A virus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=related_link\">",
"      Patient information: General travel advice (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=related_link\">",
"      Patient information: Vaccines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23619?source=related_link\">",
"      Patient information: Vaccines for adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/44/21187?source=related_link\">",
"      Patient information: Vaccines for travel (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17223?source=related_link\">",
"      Poliovirus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22793?source=related_link\">",
"      Prevention and treatment of measles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13370?source=related_link\">",
"      Prevention of malaria infection in travelers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37289?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/35/10807?source=related_link\">",
"      Quadrivalent (A, C, Y, W-135) meningococcal conjugate vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2393?source=related_link\">",
"      Rabies immune globulin and vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=related_link\">",
"      Rabies virus vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/48/8967?source=related_link\">",
"      Travel advice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/49/13081?source=related_link\">",
"      Travel advice for immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29145?source=related_link\">",
"      Travelers' diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=related_link\">",
"      Treatment and prevention of Bordetella pertussis infection in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/58/18345?source=related_link\">",
"      Treatment and prevention of typhoid fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/7/25718?source=related_link\">",
"      Typhoid vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20088?source=related_link\">",
"      When to use rabies prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/21/15705?source=related_link\">",
"      Yellow fever",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_21_2395="Risk factors for osteoporosis";
var content_f2_21_2395=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F76445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F76445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical risk factors for fracture",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Advancing age",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Previous fracture",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Glucocorticoid therapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Parental history of hip fracture",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Low body weight",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Current cigarette smoking",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Excessive alcohol consumption",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Rheumatoid arthritis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Secondary osteoporosis (eg, hypogonadism or premature menopause, malabsorption, chronic liver disease, inflammatory bowel disease)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int 2005; 16:581.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_21_2395=[""].join("\n");
var outline_f2_21_2395=null;
var title_f2_21_2396="Clinical features of PVS coma and others";
var content_f2_21_2396=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of the persistent vegetative state and related conditions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Self-awareness",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sleep-wake cycles",
"       </td>",
"       <td class=\"subtitle1\">",
"        Experience of suffering",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prognosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistent vegetative state",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        Intact",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Depends upon cause",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coma",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Usually recovery, persistent vegetative state or death in 2 to 4 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brain death",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No recovery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Locked-in syndrome",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"       <td>",
"        Intact",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Recovery unlikely, persistent quadriplegia with prolonged survival possible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Akinetic mutism",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"       <td>",
"        Intact",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Recovery very unlikely (depends on cause)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dementia",
"       </td>",
"       <td>",
"        Present but lost in late stages",
"       </td>",
"       <td>",
"        Intact",
"       </td>",
"       <td>",
"        Yes, but lost in late stages",
"       </td>",
"       <td>",
"        Irreversible (ultimate outcome depends on cause)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: N Engl J Med 1994; 330:1499.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_21_2396=[""].join("\n");
var outline_f2_21_2396=null;
var title_f2_21_2397="Causes of pruritus";
var content_f2_21_2397=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of pruritus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cutaneous disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurodermatitis",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic xerosis in the elderly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Burns and scars",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Renal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        End stage chronic renal failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Liver disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary biliary cirrhosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholestatic jaundice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholestasis of pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hematopoietic disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polycythemia vera",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iron deficiency anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mastocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hodgkin lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Non-Hodgkin lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple myeloma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Endocrine and metabolic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperthyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carcinoid syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infectious and parasitic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Superficial fungal infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scabies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Human immunodeficiency virus infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Onchocerciasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Varicella",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Autoimmune disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatomyositis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scleroderma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sj&ouml;gren syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neurologic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brachioradial pruritus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Notalgia paresthetica",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postherpetic neuralgia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebrovascular accident",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Psychogenic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychogenic excoriation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Delusional parasitosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anorexia nervosa",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Eg, dermatitis, urticaria, psoriasis, pityriasis rosea, pityriasis rubra pilaris, acne, dermatitis herpetiformis, bullous pemphigoid, linear IgA disease.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Eg, prurigo nodularis, lichen simplex chronicus, lichen amyloidosis.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_21_2397=[""].join("\n");
var outline_f2_21_2397=null;
var title_f2_21_2398="Low-fat low-sugar menus";
var content_f2_21_2398=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=32\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=32\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Low-fat, low-sugar eating guidelines sample menus*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Breakfast",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2 slices whole-grain bread or frozen waffles",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2 teaspoons almond butter",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 cup skim milk or yogurt",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 small banana",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Lunch",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Turkey sandwich (2 ounces turkey breast on a whole- grain bread or roll)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 cup green grapes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 cup baby carrots, jicama and bell pepper strips",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2 tablespoons fat-free ranch dressing",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 cup skim milk or fat-free, reduced-calorie yogurt",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bottled water or diet soda",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Dinner",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            3-4 ounces grilled salmon",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2/3 cup steamed/boiled brown rice",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2 cups mixed salad greens",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 tablespoon balsamic vinegar with 2 teaspoons olive oil",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1/2 cup steamed green beans",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Water with lemon",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Snack",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fruit smoothie",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            (1 cup skim milk, 1 cup frozen fruit such as peaches or mixed berries)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            3 cups low-fat popcorn",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 ounce peanuts",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Breakfast",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Breakfast taco (small whole-wheat flour tortilla, 1/2 cup egg substitute, 1 ounce reduced-fat cheese, 2 tablespoons salsa)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 small orange",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Lunch",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2 ounces water-packed tuna mixed with 1 tablespoon light mayonnaise, chopped celery",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            10 whole grain crackers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 small apple",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 cup skim milk or fat-free,",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            reduced-calorie yogurt",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Water or diet soda",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Dinner",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 cup vegetable soup (carrots, celery, onions, tomato)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2-3 ounces grilled chicken breast (skinless)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1/2 cup black beans",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1/2 cup steamed/boiled brown rice",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2 corn tortillas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 cup lettuce and tomato salad with 1/8 avocado slice",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Water or unsweetened iced tea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Snack",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1/2 mango",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 cup fat-free, reduced-calorie yogurt with 1 ounce almond slivers",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Breakfast",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 cup old-fashioned oatmeal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 cup skim milk",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 small pear",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Lunch",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Peanut butter sandwich on whole wheat bread",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Apple",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 cup carrot and celery sticks",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2 tablespoons light ranch dressing",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 cup skim milk or fat-free, reduced-calorie yogurt",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Water or diet soda",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Dinner",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            3-4 ounces baked barbeque chicken breast (skinless)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1/2 cup mashed sweet potato",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1/2 cup steamed cabbage",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1/2 cup steamed turnip greens",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 small whole grain roll with 1 tablespoon light margarine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Water or unsweetened iced tea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Snack",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            6 cups low-fat popcorn",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diet soda or sugar-free Kool-Aid",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * All meals are prepared without added fat.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_21_2398=[""].join("\n");
var outline_f2_21_2398=null;
var title_f2_21_2399="death censored graft Survival";
var content_f2_21_2399=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F61627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F61627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Comparison of renal allograft survival according to months on dialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 333px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Meier-Kriesche, HU, Kaplan, B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. Transplantation 2002; 74:1377.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_21_2399=[""].join("\n");
var outline_f2_21_2399=null;
